

# BMJ Paediatrics Open

BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjpaedsopen.bmj.com>).

If you have any questions on BMJ Paediatrics Open's open peer review process please email [info.bmjpo@bmj.com](mailto:info.bmjpo@bmj.com)

## BMJ Paediatrics Open

### Comparison of pediatric pulmonary and extra-pulmonary tuberculosis in Singapore

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2018-000308
Article Type:	Original article
Date Submitted by the Author:	06-May-2018
Complete List of Authors:	Loh, Sin Wee; KK Women's and Children's Hospital, Department of Pediatrics Thoon , Koh Cheng ; KK Women's and Children's Hospital, Infectious Disease Service; National University Singapore Yong Loo Lin School of Medicine Tan , Natalie Woon Hui ; KK Women's and Children's Hospital, Infectious Disease Service; National University Singapore Yong Loo Lin School of Medicine Li , Jiahui; KK Women's and Children's Hospital, Infectious Disease Service Chong , Chia Yin ; KK Women's and Children's Hospital, Infectious Disease Service; National University Singapore Yong Loo Lin School of Medicine
Keywords:	Infectious Diseases

SCHOLARONE™  
Manuscripts

# COMPARISON OF PEDIATRIC PULMONARY AND EXTRA-PULMONARY TUBERCULOSIS IN SINGAPORE

SW Loh<sup>1</sup>, KC Thoon<sup>2,3,4</sup>, NWH Tan<sup>2,3,4,5</sup>, JH Li<sup>2</sup>, CY Chong<sup>2,3,4,5</sup>

<sup>1</sup> Department of Pediatrics, KK Women's and Children's Hospital, Singapore

<sup>2</sup> Infectious Disease Service, Department of Pediatrics, KK Women's and Children's Hospital, Singapore

<sup>3</sup> Yong Loo Lin School of Medicine, National University of Singapore, Singapore

<sup>4</sup> Duke-National University of Singapore Medical School, Singapore

<sup>5</sup> Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

## Corresponding author:

Sin Wee Loh, MB BCh BAO(Ireland), MRCPCH(UK), MMED(Singapore)

Department of Pediatrics

KK Women's and Children's Hospital

100 Bukit Timah Road, Singapore 229899

Email: sinwee.loh@mohh.com.sg

Telephone: +65 96188260

## ABSTRACT

**Background:** Tuberculosis (TB) is a major cause of mortality and morbidity in the world. Each case represents on-going transmission and has a significant public health burden. We aim to (i) examine the clinical profile of paediatric TB and (ii) compare pulmonary TB (PTB) with extra-pulmonary TB (EPTB).

**Methods:** Retrospective study of patients admitted to KK Women's and Children's Hospital, Singapore, from January 2008 to September 2017 for active TB disease. We compared clinical characteristics and outcomes of patients with PTB and EPTB. Outcome of interest was recovery rate.

**Results:** Seventy-five patients were diagnosed as active TB; 65% PTB and 35% EPTB. Patients with EPTB were more likely to be younger [Median age 5.1 (interquartile range (IQR) 1.2, 10.2) vs 10.1 (IQR 3.5, 13.5) years], immunodeficient (34.6% vs 6.1%), have lower haemoglobin count [11.5 (IQR 10.2, 11.9) vs 12.0 (IQR 10.5, 13.9) g/dL] and lower recovery rate (26.9% vs 57.1%). Using positive TB culture as the gold standard, T-Spot had higher sensitivity and specificity than tuberculin skin test (TST) and combined T-Spot and TST. Overall mortality rate was 8.0%; CNS TB alone higher than PTB (28.6% vs 4.1%).

**Conclusion:** Extra-pulmonary TB is more common in the younger age group and is associated with higher mortality and sequelae rates.

## INTRODUCTION

Tuberculosis (TB) remains a major cause of morbidity and mortality in the world. Following the introduction of Singapore Tuberculosis Elimination Programme in 1997; the incidence of TB declined from 57 per 100,000 residents in the 1990s to a low of 35 per 100,000 residents in 2007. In 2016, the age-standardized incidence rate of TB was 38.7 per 100,000 residents in Singapore; children below 19 years old contributed only 2.1% of the total TB population. The majority (83.5%) of cases had pulmonary TB (PTB) with or without extra-pulmonary involvement, while the remainder (16.5%) had exclusively extra-pulmonary TB (EPTB) (1).

The presentation of TB in children can range from non-specific symptoms to severe clinical presentation; which makes diagnosis challenging. Although PTB is the most common involvement, all other organs can be involved as well (2, 3). Globally in 2014, almost 10 million people developed TB, of which EPTB represented almost 15% of the overall TB (4). In adults, proportion of EPTB to PTB has increased due to a decrease in PTB rates (5). However, little is known of the global impact of pediatric EPTB due to difficulties in pediatric TB case detection and low notification rates (6). The last published review of pediatric TB in Singapore was by Freda M. Paul in 1967, which focused on the fatality of tuberculous meningitis. With the changing demographics in Singapore, a new review of pediatric TB is needed (7, 8). The aims of this study were to (i) examine the clinical profile and treatment outcomes of pediatric TB and (ii) compare PTB with EPTB.

## METHODS

### Setting

Kandang Kerbau (KK) Women's and Children's Hospital (KKH) is the largest tertiary pediatric hospital in Singapore with approximately 350 pediatric beds. We collected data of all patients who were admitted for TB work-up in KKH from January 2008 to September 2017. Approval was obtained from the centralized institution review board of Singhealth Research.

### Patient identification and data collection

A patient list with the code tuberculosis was generated using International Classification of Disease [ICD9CM or ICD10AM (from 2012 onwards)]. Patients who were treated for active TB were included, latent TB cases were excluded. Data pertaining to demographic profile, clinical presentation, investigations and treatment of selected cases were collected from case notes, electronic records and the infectious disease database.

### Case definitions

Both microbiologically proven cases and non- microbiologically proven cases were included. Microbiologically proven cases were defined as those with positive TB culture and/or TB polymerase chain reaction (PCR). Non-microbiologically proven cases were defined as those with negative TB culture or PCR but positive TB smear, tuberculin skin test, interferon gamma release assay (IGRA) in the presence of clinical diagnosis of TB or positive CXR. EPTB was defined as any active TB case involving organs other than lungs and pleural. Multi-organ TB was defined as active TB involving 2 or more organs and was considered EPTB.

Close contact was defined as living in the same household or in frequent contact with smear

positive pulmonary TB case. Immunodeficiency was either primary immune disorders or secondary to an underlying disease or immunosuppressive drugs. Definitions of symptoms were adapted from the South African Guidelines 2013 (9);

- Significant cough was defined as cough duration of  $\geq 14$  days
- Significant fever was defined as temperature  $\geq 38^{\circ}\text{C}$  for  $\geq 14$  days
- Significant weight loss was defined as  $\geq 1\text{kg}$  for  $\geq 1$  month
- Fatigue: Patient's or parents' complaint of reduced playfulness or lethargy

In our center, T-SPOT.TB assay (Oxford Immunotec, Abingdon, United Kingdom) is the preferred type of IGRA used for children  $\geq 2$  years old because of the lower rate of indeterminate results compared to QuantiFERON-TB Gold and QuantiFERON-TB In-tube (10). Tuberculin skin test (TST) might be performed when T-spot was not available (i.e. out of office hours). Positive TST was defined as reading of  $\geq 10\text{mm}$  at 48 hours. All patients had CXR performed and reported by in-house radiologists. All our patients had microbiological investigations. Consecutive fluid specimens were sent for acid-fast bacilli (AFB) smear and culture.

The TB culture method was by the automated MGIT960 system for liquid growth and Lowenstein Jensen slants for solid growth (10, 11).

### Statistical analysis

Analysis was carried out using SPSS version 19 (IBM, Armonk, New York, USA). For categorical data, we performed chi-square tests or Fisher's exact test when cell sizes were less than 5 for univariate analysis. For continuous data, we performed Student T test for parametric data or Mann-Whitney U test for non-parametric data. A P value of  $<0.05$  was statistically significant.

## RESULTS

Seventy-five patients were included; 49 (65.3%) had PTB and 26 (34.7%) had EPTB. Further breakdown of EPTB: 5 (6.7%) lymphatic; 7 (9.3%) central nervous system (CNS); 1 (1.3%) pericardial, 2 (2.7%) gastro-intestinal; 1 (1.3%) eye, 2 (2.7%) musculoskeletal and 8 (10.7%) multi-organ TB involving  $\geq 2$  systems. Of the multi-organ TB: 2 (2.7%) had involvement of pulmonary and CNS, 1 patient (1.3%) each had involvement of CNS and lymphatics; GIT and MSK; pulmonary and GIT; pulmonary and lymphatics; GIT, lymphatics and MSK; GIT and pulmonary. The majority had no known TB contact (n=47, 62.7%) whereas 26 (34.7%) had household contact and 2 (2.7%) school contact. Table 1 describes baseline characteristics of all patients. Significant fever, cough and weight loss were the most common clinical presentation of TB. However, only 20 (26.7%) patients presented with  $\geq 2$  significant symptoms. Twelve (16.0%) patients were immunodeficient: 4 human immunodeficiency virus infection, 2 severe combined immunodeficiency, 2 malignancies (1 patient had medulloblastoma and 1 had neuroblastoma) on chemotherapy, 1 Epstein Barr Virus-related haemophagocytic lymphohistiocytosis, 1 mendelian susceptibility to mycobacterial disease, 1 juvenile idiopathic arthritis on biologics and 1 Crohn's disease on immunosuppressant.

Abnormal CXR was found in 51 patients (68.0%) with the following changes: pulmonary infiltrates (n=24,32.0%), hilar adenopathy (n=7,9.3%), military (n=4,5.3%), lobar collapse (n=3, 4.0%), pleural changes (n=2, 2.7%), cavitation (n=2, 2.7%), widened mediastinum (n=1,1.3%) and combination of findings (n=8,10.7%). Patients with PTB were more likely to have abnormal CXR compared to those with EPTB (p<0.01). The majority of patients (n=45, 60.0%) had



1  
2  
3 microbiologically proven TB. Twenty (26.7%) had at least one positive AFB smear and 39  
4 (52%) had at least one positive TB culture. TB PCR was sent in 55 patients (73.3%); 26 (47.3%)  
5  
6 were positive and 29 (52.7%) were negative.  
7  
8  
9

10  
11 Comparing EPTB with PTB (Table 2), patients with EPTB were younger [Median age 5.05 years  
12 (interquartile range (IQR) 1.23, 10.23) vs 10.10 years (IQR 3.47, 13.45),  $p=0.03$ ], more likely to  
13 be immunodeficient ( $p<0.01$ ) and had lower hemoglobin (Hb) level [Median Hb level 11.15 g/dL  
14 (IQR 10.23, 11.90) vs 12.00 g/dL (IQR 10.50, 13.85),  $p=0.01$ ]. BCG vaccination rate was lower  
15 in the EPTB group compared to the PTB group (76.0% vs 89.3%,  $p=0.14$ ). All patients received  
16 isoniazid and rifampicin with pyrazinamide and/or ethambutol. Patients with extra-pulmonary  
17 TB needed longer duration of treatment compared to those with pulmonary TB [Median 12 (IQR  
18 9, 12) vs 6 (IQR 6, 9) months,  $p<0.01$ ]. Patients who were immunodeficient were also treated for  
19 a longer period compared to immunocompetent patients [Median 12 (IQR 9.8, 12.0) vs 6 (IQR 6,  
20 9) months,  $p<0.01$ ].  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

34  
35 Overall mortality rate was 8.0% with higher mortality rate of CNS TB than pulmonary TB  
36 (28.6% vs 4.1%,  $p=0.02$ ). Mortality rate for EPTB was 15.4%. PTB patients were more likely to  
37 fully recover compared to EPTB (57.1% vs 26.9%,  $p=0.01$ ). Sequelae were found in 9 PTB  
38 (18.4%, bronchiectasis 3, restrictive lung disease 2, bronchus compression 3 and complications  
39 from underlying conditions 2), 9 EPTB (34.6%, intestinal perforation 1, kyphosis 1, CNS infarct  
40 1, seizures 2, developmental delay 2, complications from underlying conditions 2) and 4 CNS  
41 TB (57.1%, seizures 2, developmental delay 2).  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52 T-Spot was performed in 41 (54.7%) patients: 32 (78.0%) positive, 6 (14.6%) negative and 3  
53 (7.3%) indeterminate. TST was performed in 31 patients (41.3%): 26 (83.9%) positive and the  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 median reading was 14.5 mm (IQR 11, 20). Thirteen (17.3%) patients had both positive T-Spot  
4 and TST. Table 3 describes the sensitivity and specificity of AFB smear, TB PCR, IGRA and  
5  
6 TST in predicting active TB infection using positive TB culture as the reference standard for  
7  
8 active TB disease. The sensitivity and specificity of T-Spot for active TB disease were higher  
9  
10 than that of TST but similar to combined T-Spot and TST.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

Our study compares the demographics, clinical spectrum and investigation results of PTB and EPTB.

The median age of patients with EPTB was significantly younger than PTB [Median age 5.05 vs 10.10 years,  $p=0.03$ ], similar to another paediatric TB study (12). EPTB had lower recovery rate, high mortality, relapse and sequelae rates compared to PTB. Similar to other studies, this implied that younger children had higher risk of serious TB (13, 14). Mortality rate for CNS TB was significantly higher than pulmonary TB (28.6% vs 4.1%,  $p=0.02$ ). The mortality of TB meningitis from our review had decreased drastically from a peak of 60% in 1955 (7, 8). Mass BCG vaccination campaign, implemented in 1957, was one of the key interventions that led to a marked decrease in TB mortality rates, especially EPTB and for children < 5 years old (15, 16). Similar to a retrospective pediatric study in China, more patients had no BCG vaccination in the EPTB group (76.0% vs 89.1%) even though the difference was not significant (12). This finding suggests that children who received BCG vaccination might have less chance of contracting EPTB. Clinical trials are needed to further ascertain the protectiveness of the vaccination towards EPTB.

Children with TB rarely present with classical symptoms as seen in a survey from a high burden community (17). This is similar to our study in which only 26.7% of patients presented with  $\geq 2$  out of 5 significant symptoms stated by South African Society for Pediatric Infectious Diseases (9). Marais et al stated that the index of suspicion should be increased when symptoms such as

1  
2  
3 prolonged cough of more than 2 weeks, significant weight loss and fatigue exist together with  
4 positive TB contact (18). Four (5.3%) of our patients with TB had  $\geq 2$  significant symptoms and  
5  
6 positive contact history. Nevertheless, available scoring systems should not be used for  
7  
8 predicting pediatric TB infection as they lack sensitivity and specificity (19).  
9  
10

11  
12 Sixty-eight percent of patients had abnormal CXR, which was higher than a large-scale  
13  
14 multicenter center study conducted in India (20). This can be explained by significant variation  
15  
16 between radiologists when interpreting pediatric CXR (21). Moreover, CXR had a high  
17  
18 sensitivity but low specificity for detecting active TB as many radiological changes seen in TB  
19  
20 could be present in other infections (22).  
21  
22  
23

24  
25 A positive microbiological culture remains the gold standard for diagnosis of active TB but is  
26  
27 often limited by the prolonged turnover time. In this study, the percentage of patients with  
28  
29 eventual positive TB culture (49.0% and 57.5%) was more than those with  $\geq 1$  positive AFB  
30  
31 smear (26.5% and 28.0%) in both the PTB and EPTB group, which could lead to a delay in  
32  
33 identification and treatment of active TB disease. Our higher TB culture rates compared to  
34  
35 15.7% in China and 34% in USA could be due to more aggressive sampling methods or different  
36  
37 culture methods (12, 23).  
38  
39  
40

41  
42 Immunological investigations such as TST and IGRA can aid in the diagnosis of TB but each has  
43  
44 its own limitations. In children  $< 4$  years old, T-Spot is preferred as it has lower rate of  
45  
46 indeterminate results compared to QuantiFERON-TB test (24). While IGRA and TST are good  
47  
48 predictors of latent TB infection, their sensitivity for active TB infection are much more limited  
49  
50 (25, 26). However, if we considered positive TB culture as the reference standard for diagnosis  
51  
52 of active TB, T-spot had the highest sensitivity followed by TB PCR and TST in this study  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (85.7%, 74.1% and 73.3% respectively). These findings were similar to a meta-analysis that  
4 consisted of predominantly adult populations (27). In contrast to our findings, a retrospective  
5 study of active TB cases in 6 large pediatric centers in United Kingdom found out that IGRA  
6 was no more sensitive than a TST of >15mm in predicting active TB infection (28). This could  
7 be due to increased threshold for specificity by increasing the cut-off for TST from 10mm to  
8 15mm. In the same study, a combination of both TST and IGRA correctly predicted more than  
9 90% of culture positive cases, which was similar to our findings (28). Regardless of TST or  
10 IGRA results, treatment for TB should not be delayed if factors are strongly suggestive of TB  
11 (contact history, radiologic and microbiologic) (29).  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 The limitations of this study were the small sample size and its retrospective nature. It was not  
26 powered to correlate the effect of age, gender, and symptoms to laboratory results. This study  
27 only included patients who received inpatient treatment for TB in KKH, potentially missing the  
28 less severe group who received outpatient therapy.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## CONCLUSION

EPTB is more common in the younger age group and is associated with higher mortality and sequelae rates. As TB culture has a long turnover time, treatment for TB should not be delayed if other factors are strongly suggestive of TB. Clinicians should have a high index of suspicion for EPTB and should pay special attention to the younger age group.

**What is already known on this topic**

Diagnosis of pediatric TB can be challenging as presentation ranges from non-specific symptoms to severe clinical presentation. The proportion of EPTB has increased in the adult population. However, little is known about the global impact of pediatric EPTB.

**What this study adds**

Locally, this study aims to re-examine the clinical profile and treatment outcomes of pediatric TB in Singapore. Globally, this study aims to add new information to the differences between pediatric PTB and EPTB.

## REFERENCES

1. Ministry of Health, Singapore. Communicable Diseases Surveillance in Singapore 2016, Singapore. p. 103 - 15.
2. Yang Z, Kong Y, Wilson F, Foxman B, Fowler AH, Marrs CF, et al. Identification of risk factors for extrapulmonary tuberculosis. *Clin Infect Dis*. 2004;38(2):199-205.
3. Gonzalez OY, Adams G, Teeter LD, Bui TT, Musser JM, Graviss EA. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. *Int J Tuberc Lung Dis*. 2003;7(12):1178-85.
4. World Health Organization. Global Tuberculosis Report 2015. Geneva; 2015. .
5. Sandgren A, Hollo V, van der Werf MJ. Extrapulmonary tuberculosis in the European Union and European Economic Area, 2002 to 2011. *Euro Surveill*. 2013;18(12).
6. Santiago-García B, Blázquez-Gamero D, Baquero-Artigao F, Ruíz-Contreras J, Bellón JM, Muñoz-Fernández MA, et al. Pediatric Extrapulmonary Tuberculosis: Clinical Spectrum, Risk Factors and Diagnostic Challenges in a Low Prevalence Region. *Pediatr Infect Dis J*. 2016;35(11):1175-81.
7. PAUL FM. Tuberculosis in B.C.G. vaccinated children in Singapore. *Arch Dis Child*. 1961;36:530-6.
8. Paul F. Tuberculosis meningitis in children in the Department of Paediatrics over a ten-year period. *Singapore Med J*. 1967;8(2):102-10.
9. Moore D, Hani C, H Hospital B, Schaaf S, Marais B, Moore D, et al. Childhood tuberculosis guidelines of the Southern African Society for Paediatric Infectious Diseases (SASPID)2009.
10. Chee CB, Gan SH, Khinmar KW, Barkham TM, Koh CK, Liang S, et al. Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. *J Clin Microbiol*. 2008;46(6):1935-40.
11. Chan DS, Choy MY, Wang S, Sng LH. An evaluation of the recovery of mycobacteria from urine specimens using the automated Mycobacteria Growth Indicator Tube system (BACTEC MGIT 960). *J Med Microbiol*. 2008;57(Pt 10):1220-2.
12. Wu X-R, Yin Q-Q, Jiao A-X, Xu B-P, Sun L, Jiao W-W, et al. Pediatric Tuberculosis at Beijing Children's Hospital: 2002–2010. *Pediatrics*. 2012;130(6):e1433.
13. Moyo S, Verver S, Mahomed H, Hawkrigde A, Kibel M, Hatherill M, et al. Age-related tuberculosis incidence and severity in children under 5 years of age in Cape Town, South Africa. *Int J Tuberc Lung Dis*. 2010;14(2):149-54.
14. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric tuberculosis. *Lancet Infect Dis*. 2008;8(8):498-510.
15. Chew CH, Hu PY. BCG programme in the Republic of Singapore. *Singapore Med J*. 1974;15(4):241-5.
16. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. *JAMA*. 1994;271(9):698-702.



17. Marais BJ, Obihara CC, Gie RP, Schaaf HS, Hesselting AC, Lombard C, et al. The prevalence of symptoms associated with pulmonary tuberculosis in randomly selected children from a high burden community. *Arch Dis Child*. 2005;90(11):1166-70.
18. Marais BJ, Gie RP, Hesselting AC, Schaaf HS, Lombard C, Enarson DA, et al. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. *Pediatrics*. 2006;118(5):e1350-9.
19. Hesselting AC, Schaaf HS, Gie RP, Starke JR, Beyers N. A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. *Int J Tuberc Lung Dis*. 2002;6(12):1038-45.
20. Swaminathan S, Datta M, Radhamani MP, Mathew S, Reetha AM, Rajajee S, et al. A profile of bacteriologically confirmed pulmonary tuberculosis in children. *Indian Pediatr*. 2008;45(9):743-7.
21. Hoog AH, Meme HK, van Deutekom H, Mithika AM, Olunga C, Onyino F, et al. High sensitivity of chest radiograph reading by clinical officers in a tuberculosis prevalence survey. *Int J Tuberc Lung Dis*. 2011;15(10):1308-14.
22. Piccazzo R, Paparo F, Garlaschi G. Diagnostic accuracy of chest radiography for the diagnosis of tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review. *J Rheumatol Suppl*. 2014;91:32-40.
23. Winston CA, Menzies HJ. Pediatric and Adolescent Tuberculosis in the United States, 2008–2010. *Pediatrics*. 2012;130(6):e1425.
24. Bergamini BM, Losi M, Vaianti F, D'Amico R, Meccugni B, Meacci M, et al. Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. *Pediatrics*. 2009;123(3):e419-24.
25. Connell T, Tebruegge M, Ritz N, Curtis N. Interferon-gamma release assays for the diagnosis of tuberculosis. *Pediatr Infect Dis J*. 2009;28(8):758-9.
26. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. *Ann Intern Med*. 2007;146(5):340-54.
27. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. *Ann Intern Med*. 2008;149(3):177-84.
28. Bamford AR, Crook AM, Clark JE, Nademi Z, Dixon G, Paton JY, et al. Comparison of interferon-gamma release assays and tuberculin skin test in predicting active tuberculosis (TB) in children in the UK: a paediatric TB network study. *Arch Dis Child*. 2010;95(3):180-6.
29. Perez-Velez CM, Marais BJ. Tuberculosis in Children. *New England Journal of Medicine*. 2012;367(4):348-61.

**Table 1. Characteristics of Pediatric Patients with TB (n=75)**

Characteristics	Results (%)
Median Age (years)	8.8 (IQR 2.6, 13.1)
Age group	
0 - 1.9 years	15 (20.0)
2.0 - 4.9 years	12 (16.0)
≥ 5 years	48 (64.0)
Gender	
Male	39 (52.0)
Female	36 (48.0)
Nationality	
Singapore residents	53 (70.7)
Non-Singapore residents	22 (29.3)
BCG vaccination (missing 4)	
Received	60 (80.0)
Not received	11 (14.7)
TB Sites	
Pulmonary	49 (65.3)
Extra-pulmonary	26 (34.7)
Comorbidities (missing 1)	
Immune-deficient	12 (16.2)
Not immune-deficient	62 (83.3)
Contact history	
Positive contact	28 (37.3)
No contact history	47 (62.7)
Symptoms	
Significant fever	20 (26.7)
Significant cough	25 (33.3)
Significant weight loss	24 (32.0)
Fatigue	4 (5.3)
Lymphadenopathy	10 (13.3)
≥ 2 symptoms stated above	20 (26.7)
No symptom stated above	33 (44.0)
Microbiological	
Microbiologically proven	45 (60.0)
Not microbiologically proven	30 (40.0)
Microbiological results	
≥ 1 site/sample positive AFB smear	20 (26.7)
≥ 1 site/ sample positive TB culture	39 (52.0)
≥ 1 site/sample positive TB PCR	26 (34.7)
Treatment outcome	
Recovered	35 (46.3)
Death	6 (8.0)
Relapsed	2 (2.7)
Sequelae	19 (25.3)

Lost to follow up	11 (14.6)
Still completing treatment	2 (2.7)

**Table 2. Comparison of Pulmonary and Extra-pulmonary TB**

	Pulmonary N= 49 (%)	Extra-pulmonary N= 26 (%)	P value
Median age (years)	10.1 (IQR 3.5, 13.5)	5.1 (IQR 1.2, 10.2)	0.03
Gender			0.82
Males	25 (51.0)	14 (53.8)	
Females	24 (49.0)	12 (46.2)	
Nationality			0.21
Singapore residents	37 (75.5)	16 (61.5)	
Non-Singapore residents	12 (24.5)	10 (38.5)	
Received BCG vaccine	41 (89.1)	19 (76.0)	0.14
Comorbidities			<0.01
Immune-deficient	3 (6.1)	9 (34.6)	
Not immune-deficient	46 (93.9)	17 (65.4)	
Contact history			0.06
Positive contact	22 (44.9)	6 (23.1)	
No contact history	27 (55.1)	20 (76.9)	
Symptoms			
Significant fever	9 (19.1)	11 (47.8)	0.01
Significant cough	22 (51.2)	3 (13.6)	<0.01
Significant weight loss	18 (39.1)	6 (27.3)	0.34
Fatigue	2 (4.2)	2 (8.3)	0.60
Lymphadenopathy	2 (4.1)	8 (30.8)	<0.01
≥ 2 symptoms stated above	14 (28.6)	5 (23.1)	0.61
No symptom stated above	22 (44.9)	11 (42.3)	0.83
Hematological results			
Median hemoglobin (g/dL)	12.0 (IQR 10.5, 13.9)	11.2 (IQR 10.2, 11.9)	0.03
Median white blood cells (x10 <sup>9</sup> /L)	11.2 (IQR 7.5, 15.6)	10.2 (IQR 7.6, 12.0)	0.15
Median Platelet (x10 <sup>9</sup> /L)	376.5 (IQR 281.5, 451.0)	377.0 (IQR 339.5, 507.0)	0.38
Median ESR (mm/hr)	40.0 (IQR 15.0, 85.0)	34.0 (IQR 19.0, 54.5)	0.61
Median CRP (mg/L)	36.0 (IQR 16.5, 84.4)	32.4 (IQR 8.6, 69.3)	0.43
Immunological results			
Positive TST	20 (40.8)	6 (23.1)	0.10
Positive IGRA	20 (40.8)	12 (46.2)	0.80
Microbiological			0.10
Microbiologically proven	26 (53.1)	19 (73.1)	
Not microbiologically proven	23 (46.9)	7 (26.9)	
Microbiological results			
≥ 1 site/sample positive AFB smear	13 (26.5)	7 (28.0)	0.89
≥ 1 site/sample positive AFB culture	24 (49.0)	15 (57.7)	0.47
≥ 1 site/sample positive TB PCR	14 (40.0)	12 (60.0)	0.15
Abnormal CXR	41 (83.7)	10 (38.5)	<0.01
Treatment outcome			0.01
Recovered	28 (57.1)	7 (26.9)	

Death	2 (4.1)	4 (15.4)	0.17
Relapsed	1 (2.0)	1 (3.8)	-
Sequelae	10 (20.4)	9 (34.6)	0.18
Lost to follow up	8 (16.3)	3 (11.5)	0.73
Still completing treatment	0 (0.0)	2 (7.7)	-
Median duration of treatment (months)	6.0 (IQR 6.0, 9.0)	12.0 (IQR 9.0, 12.0)	<0.01

**Table 3. Sensitivity and specificity of investigations**

	≥1 TB Culture		Sensitivity (95% CI)	Specificity (95% CI)	Positive predictive value (95% CI)	Negative predictive value (95% CI)
	Positive	Negative				
≥1 AFB Smear (n=74, missing 1)						
Positive	14	6	35.9 (21.2- 52.8)	82.9 (66.4-93.4)	70.0 (50.2-84.4)	53.7 (46.7-60.5)
Negative	25	29				
≥1 TB PCR (n=55)						
Positive	20	6	74.1 (53.7-88.9)	78.6 (59.1-91.7)	76.9 (61.3-87.5)	75.9 (61.8-85.9)
Negative	7	22				
T-Spot (n=41)						
Positive	18	14	85.7 (63.7-97.0)	30.0 (11.9-54.3)	56.3 (47.9-64.3)	66.7 (36.6-87.4)
Negative	3	6				
TST (n=31)						
Positive	11	15	73.3 (49.9-92.2)	6.3 (0.2-30.2)	42.3 (34.5-50.5)	20.0 (3.0-66.6)
Negative	4	1				
Combining TST and T-Spot (n=59)						
1 or both positive	25	25	86.2 (68.3-96.1)	16.7 (5.6-34.7)	50.0 (44.6-55.4)	55.6 (27.1-80.8)
Both negative	4	5				

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Confidential: For Review Only

# BMJ Paediatrics Open

## Paediatric Tuberculosis in Singapore - A Retrospective Review

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2018-000308.R1
Article Type:	Original article
Date Submitted by the Author:	16-Jul-2018
Complete List of Authors:	Loh, Sin Wee; KK Women's and Children's Hospital, Department of Pediatrics Thoon , Koh Cheng ; KK Women's and Children's Hospital, Infectious Disease Service; National University Singapore Yong Loo Lin School of Medicine Tan , Natalie Woon Hui ; KK Women's and Children's Hospital, Infectious Disease Service; National University Singapore Yong Loo Lin School of Medicine Li , Jiahui; KK Women's and Children's Hospital, Infectious Disease Service Chong , Chia Yin ; KK Women's and Children's Hospital, Infectious Disease Service; National University Singapore Yong Loo Lin School of Medicine
Keywords:	Infectious Diseases

SCHOLARONE™  
Manuscripts

1  
2  
3 **1 PAEDIATRIC TUBERCULOSIS IN SINGAPORE – A RETROSPECTIVE**  
4  
5  
6 **2 REVIEW**  
7

8  
9 **3 SW Loh<sup>1</sup>, KC Thoon<sup>2,3,4</sup>, NWH Tan<sup>2,3,4,5</sup>, JH Li<sup>2</sup>, CY Chong<sup>2,3,4,5</sup>**  
10

11  
12 <sup>1</sup> Department of Pediatrics, KK Women's and Children's Hospital, Singapore  
13

14  
15 <sup>2</sup> Infectious Disease Service, Department of Pediatrics, KK Women's and Children's Hospital,  
16  
17  
18 Singapore  
19

20  
21 <sup>3</sup> Yong Loo Lin School of Medicine, National University of Singapore, Singapore  
22

23  
24 <sup>4</sup> Duke-National University of Singapore Medical School, Singapore  
25

26  
27 <sup>5</sup> Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore  
28  
29

30  
31 **10 Corresponding author:**  
32

33  
34 Sin Wee Loh, MB BCh BAO(Ireland), MRCPCH(UK), MMED(Singapore)  
35

36  
37 Department of Pediatrics  
38

39  
40 KK Women's and Children's Hospital  
41

42  
43 100 Bukit Timah Road, Singapore 229899  
44

45  
46 Email: sinwee.loh@mohh.com.sg  
47

48  
49 Telephone: +65 96188260  
50  
51

52  
53 17  
54  
55  
56  
57  
58  
59  
60

## 1 Acknowledgements

2 SW Loh, KC Thoon and CY Chong were involved in the design of the study. SW Loh was in  
3 charge of acquisition of data, interpretation of data and drafting of the manuscript. KC Thoon,  
4 NWH Tan, JH Li and CY Chong were involved in revising and approval of the final manuscript.  
5 CY Chong provided mentorship throughout the project.

6 Conflicts of interest: None

7



## 1 ABSTRACT

2 **Background:** Tuberculosis (TB) is a major cause of mortality and morbidity in the world. Each  
3 case represents on-going transmission and has a significant public health burden. We aim to (i)  
4 examine the clinical profile of paediatric TB and (ii) compare pulmonary TB (PTB) with extra-  
5 pulmonary TB (EPTB) in Singapore.

6 **Methods:** Retrospective study of patients admitted to KK Women's and Children's Hospital,  
7 Singapore, from January 2008 to September 2017 for active TB disease. We compared clinical  
8 characteristics and outcomes of patients with PTB and EPTB.

9 **Results:** Seventy-five patients were diagnosed as active TB; 65% PTB and 35% EPTB. Patients  
10 with EPTB were more likely to be younger [Median age 5.1 (interquartile range (IQR) 1.2, 10.2)  
11 vs 10.1 (IQR 3.5, 13.5) years], immunodeficient (35% vs 6%), had lower haemoglobin count  
12 [Median 11.5 (IQR 10.2, 11.9) vs 12.0 (IQR 10.5, 13.9) g/dL], lower recovery rate (27% vs  
13 57%) and required longer duration of treatment [Median 12 (IQR 9, 12) vs 6 (IQR 6,9) months].  
14 BCG vaccination rate was lower in the EPTB group compared to the PTB group (76% vs 89%).  
15 Overall mortality rate was 8.0%; Central nervous system (CNS) TB alone higher than PTB (29%  
16 vs 4%).

17 **Conclusion:** Extra-pulmonary TB is more common in the younger age group and is associated  
18 with lower recovery rate, higher rates of sequelae and mortality.

19  
20

Confidential: For Review Only

1

2

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 INTRODUCTION

2 Tuberculosis (TB) remains a major cause of morbidity and mortality in the world. Following the  
3 introduction of Singapore Tuberculosis Elimination Programme in 1997; the incidence of TB  
4 declined from 57 per 100,000 residents in the 1990s to a low of 35 per 100,000 residents in 2007.  
5 In 2016, the incidence rate of TB was 38.7 per 100,000 residents in Singapore; children below 19  
6 years old contributed only 2.1% of the total TB population. The majority (84%) of cases had  
7 pulmonary TB (PTB) with or without extra-pulmonary involvement, while the remainder (17%)  
8 had exclusively extra-pulmonary TB (EPTB) (1).

9 The presentation of TB in children can range from non-specific symptoms to severe clinical  
10 presentation; which makes diagnosis challenging. Although PTB is the most common  
11 involvement, all other organs can be involved as well (2, 3). Globally in 2014, almost 10 million  
12 people developed TB, of which EPTB represented almost 15% of the overall TB (4). In adults,  
13 proportion of EPTB to PTB has increased due to a decrease in PTB rates (5). However, little is  
14 known of the global impact of pediatric EPTB due to difficulties in pediatric TB case detection  
15 and low notification rates (6). The last published review of pediatric TB in Singapore was by  
16 Freda M. Paul in 1967, which focused on the fatality of tuberculous meningitis. With the  
17 changing demographics in Singapore, a new review of pediatric TB is needed (7, 8). The aims of  
18 this study were to (i) examine the clinical profile and treatment outcomes of pediatric TB and (ii)  
19 compare PTB with EPTB.

## 1 METHODS

### 2 Setting

3 Kandang Kerbau (KK) Women's and Children's Hospital (KKH) is the largest tertiary pediatric  
4 hospital in Singapore with approximately 350 pediatric beds, and accounts for 54% of pediatric  
5 admissions nationally (based on market trends, Corporate communications, KKH). We collected  
6 data of all patients who were admitted for TB work-up in KKH from January 2008 to September  
7 2017. Approval was obtained from the centralized institution review board of Singhealth  
8 Research.

### 9 Patient identification and data collection

10 A patient list with the code tuberculosis was generated using International Classification of  
11 Disease [ICD9CM or ICD10AM (from 2012 onwards)]. Patients who were treated for active TB  
12 were included, latent TB cases were excluded. Data pertaining to demographic profile, clinical  
13 presentation, investigations and treatment of selected cases were collected from case notes,  
14 electronic records and the infectious disease database.

### 15 Case definitions

16 Both microbiologically proven cases and non- microbiologically proven cases were included.  
17 Microbiologically proven cases were defined as those with positive TB culture and/or TB  
18 polymerase chain reaction (PCR). Non-microbiologically proven cases were defined as those  
19 with negative TB culture or PCR but positive TB smear, tuberculin skin test, interferon gamma  
20 release assay (IGRA) in the presence of clinical diagnosis of TB or suggestive chest X-ray  
21 (CXR). EPTB was defined as any active TB case involving organs other than lungs and pleural.

1 Multi-organ TB was defined as active TB involving 2 or more organs and was considered EPTB.

2 CNS TB (subset of EPTB) was defined as TB meningitis or meningoencephalitis.

3 Close contact was defined as living in the same household or in frequent contact with smear  
4 positive pulmonary TB case. Immunodeficiency was either primary immune disorders or  
5 secondary to an underlying disease or immunosuppressive drugs. Definitions of symptoms were  
6 adapted from the South African Guidelines 2013 (9);

- 7 • Significant cough was defined as cough duration of  $\geq 14$  days
- 8 • Significant fever was defined as temperature  $\geq 38^{\circ}\text{C}$  for  $\geq 14$  days
- 9 • Significant weight loss was defined as  $\geq 1\text{kg}$  for  $\geq 1$  month. Weight loss was  
10 further expressed as a percentage of body weight at diagnosis.
- 11 • Fatigue: Patient's or parents' complaint of reduced playfulness or lethargy

12 In our center, T-SPOT.TB assay (Oxford Immunotec, Abingdon, United Kingdom) is the  
13 preferred type of IGRA used for children  $\geq 2$  years old because of the lower rate of indeterminate  
14 results compared to QuantiFERON-TB Gold and QuantiFERON-TB In-tube (10). Tuberculin  
15 skin test (TST) might be performed when T-spot was not available (i.e. out of office hours).  
16 Positive TST was defined as reading of  $\geq 10\text{mm}$  at 48 hours. All patients had CXR performed  
17 and reported by in-house radiologists. All our patients had microbiological investigations.  
18 Consecutive fluid specimens were sent for acid-fast bacilli (AFB) smear and culture. The TB  
19 culture method was by the automated MGIT960 system for liquid growth and Lowenstein Jensen  
20 slants for solid growth (10, 11). Multi-drug-resistant TB (MDR-TB) was defined as resistance to  
21 both rifampicin and isoniazid.

## 22 **Statistical analysis**

1 Analysis was carried out using SPSS version 19 (IBM, Armonk, New York, USA). Categorical  
2 data were expressed as counts and percentages whereas continuous data were expressed as  
3 median and interquartile ranges (IQR). Differences between categorical data were analysed by  
4 chi-square tests or Fisher's exact test when cell sizes were less than 5. Differences between  
5 continuous data were analysed by Mann-Whitney test. All statistical tests were 2-tailed and a P  
6 value of <0.05 was statistically significant.

## 1 RESULTS

2 Seventy-five patients were included; 49 (65%) had PTB and 26 (35%) had EPTB. Further  
3 breakdown of EPTB: 5 lymphatic; 7 central nervous system (CNS); 1 pericardial, 2 gastro-  
4 intestinal; 1 eye, 2 musculoskeletal and 8 multi-organ TB. Of the multi-organ TB: 2 had  
5 involvement of pulmonary and CNS, 1 patient each had involvement of CNS and lymphatics;  
6 GIT and MSK; pulmonary and GIT; pulmonary and lymphatics; GIT, lymphatics and MSK; GIT  
7 and pulmonary.

8 Table 1 describes the differences between PTB and EPTB. Patients with EPTB were younger  
9 [Median age 5.05 years (IQR 1.23, 10.23) vs 10.10 years (IQR 3.47, 13.45),  $p=0.03$ ], more likely  
10 to be immunodeficient (35% vs 6%,  $p<0.01$ ) and had lower hemoglobin (Hb) level [Median Hb  
11 level 11.15 g/dL (IQR 10.23, 11.90) vs 12.00 g/dL (IQR 10.50, 13.85),  $p=0.01$ ]. BCG  
12 vaccination rate was lower in the EPTB group compared to the PTB group (76% vs 89%,  
13  $p=0.14$ ). Common clinical presentations of both PTB and EPTB were significant fever (27%),  
14 cough (33%) and weight loss (32%). However, only 20 (27%) of our patients presented with  $\geq 2$   
15 significant symptoms. Patients with PTB were more likely to have significant cough whereas  
16 those with EPTB were more likely to present with significant fever and/or lymphadenopathy  
17 (Table 1). Twenty-eight patients (37%) had positive TB contact; 26 household contacts and 2  
18 school contacts. Only 4 (5%) patients had  $\geq 2$  significant symptoms and positive contact history.

19 Abnormal CXR was found in 51 patients (68%) with the following changes: pulmonary  
20 infiltrates ( $n=24$ , 32%), hilar adenopathy ( $n=7$ , 9%), military ( $n=4$ , 5%), lobar collapse ( $n=3$ ,  
21 4%), pleural changes ( $n=2$ , 3%), cavitation ( $n=2$ , 3%), widened mediastinum ( $n=1$ , 1%) and  
22 combination of findings ( $n=8$ , 11%). Patients with PTB were more likely to have abnormal CXR

1 compared to those with EPTB (84% vs 39%,  $p<0.01$ ).

2 More than half of PTB and EPTB had microbiologically proven disease (53% and 73%  
3 respectively). T-Spot was performed in 41 (55%) patients: 32 (78%) positive, 6 (15%) negative  
4 and 3 (7%) indeterminate. TST was performed in 31 patients (41%): 26 (84%) positive with  
5 median reading was 14.5 mm (IQR 11.0, 20.0). However, there were no significant differences in  
6 the percentage of positive smear, culture, PCR, TST or T-Spot disease between PTB and EPTB.  
7 There were no cases of MDR-TB in our cohort.

8 All patients received isoniazid and rifampicin with pyrazinamide and/or ethambutol. Patients  
9 with EPTB needed longer duration of treatment compared to those with PTB [Median 12 (IQR 9,  
10 12) vs 6 (IQR 6, 9) months,  $p<0.01$ ]. Twelve (16.0%) patients were immunodeficient; Table 2  
11 describes the types of immunodeficiencies in both PTB and EPTB patients Patients who were  
12 immunodeficient were also treated for a longer period compared to immunocompetent patients  
13 [Median 12 (IQR 10, 12) vs 6 (IQR 6, 9) months,  $p<0.01$ ].

14 Overall mortality rate was 8.0%. Mortality rate of PTB and EPTB was 4% vs 15% ( $p=0.17$ ).  
15 Event-free survival in PTB patients compared to EPTB was 57% vs 27% ( $p=0.01$ ). For CNS TB  
16 alone, the mortality rate was higher than that of PTB (29% vs 4%,  $p=0.02$ ). Event-free survival  
17 in CNS TB was only 71%. CNS TB accounted for almost all mortality and sequelae in EPTB.  
18 Table 3 describes the details of sequelae, mortality and relapse cases of PTB and EPTB.

19  
20  
21



## 1 DISCUSSION

2 Our study compares the demographics, clinical spectrum, investigation results and outcomes of  
3 PTB and EPTB.

4 The median age of patients with EPTB was significantly younger than PTB [Median age 5.05 vs  
5 10.10 years,  $p=0.03$ ], similar to another paediatric TB study (12). EPTB had lower recovery rate,  
6 high mortality, relapse and sequelae rates compared to PTB. Similar to other studies, this implied  
7 that younger children had higher risk of serious TB (13, 14). Mortality rate for CNS TB was  
8 significantly higher than PTB (29% vs 4%,  $p=0.02$ ). The mortality of TB meningitis from our  
9 review had decreased drastically from a peak of 60% in 1955 (7, 8). Mass BCG vaccination  
10 campaign, implemented in 1957, was one of the key interventions that led to a marked decrease  
11 in TB mortality rates, especially EPTB and for children < 5 years old (15, 16). A retrospective  
12 pediatric study in China showed that EPTB was more prevalent in the BCG unvaccinated group  
13 (59% vs 41%,  $p=0.05$ ); our study showed similar results that more patients had no BCG  
14 vaccination in the EPTB group compared to PTB group (76% vs 89%) even though the  
15 difference was not significant (12). This finding suggests that children who received BCG  
16 vaccination have less chance of contracting EPTB.

17 Children with TB rarely present with classical symptoms as seen in a survey from a high burden  
18 community (17). This is similar to our study in which only 27% of patients presented with  $\geq 2$   
19 out of 5 significant symptoms stated by South African Society for Pediatric Infectious Diseases  
20 (9). Marais et al stated that the index of suspicion should be increased when symptoms such as  
21 prolonged cough of more than 2 weeks, significant weight loss and fatigue exist together with  
22 positive TB contact (18). Four (5%) of our patients with TB had  $\geq 2$  significant symptoms and

1 positive contact history. Nevertheless, available scoring systems should not be used for  
2 predicting pediatric TB infection as they lack sensitivity and specificity (19).

3 Sixty-eight percent of patients had abnormal CXR, which was higher than a large-scale  
4 multicenter center study conducted in India (20). This can be explained by significant variation  
5 between radiologists when interpreting pediatric CXR (21). Moreover, CXR had a high  
6 sensitivity but low specificity for detecting active TB as many radiological changes seen in TB  
7 could be present in other infections (22).

8 A positive microbiological culture remains the gold standard for diagnosis of active TB but is  
9 often limited by the prolonged turnover time. In this study, the percentage of patients with  
10 eventual positive TB culture (49.0% and 57.5%) was more than those with  $\geq 1$  positive AFB  
11 smear (26.5% and 28.0%) in both the PTB and EPTB group, which could lead to a delay in  
12 identification and treatment of active TB disease. Our higher TB culture rates compared to  
13 15.7% in China and 34% in USA could be due to more aggressive sampling methods or different  
14 culture methods (12, 23).

15 Immunological investigations such as TST and IGRA can aid in the diagnosis of TB but each has  
16 its own limitations. In children  $< 4$  years old, T-Spot is preferred as it has lower rate of  
17 indeterminate results compared to QuantiFERON-TB test (24). While IGRA and TST are good  
18 predictors of latent TB infection, their sensitivity for active TB infection are much more limited  
19 (25, 26). Regardless of TST or IGRA results, treatment for TB should not be delayed if factors  
20 are strongly suggestive of TB (contact history, radiologic and microbiologic) (27).

21 The limitations of this study were the small sample size and its retrospective nature. It was not  
22 powered to correlate the effect of age, gender, and symptoms to laboratory results. This study

1  
2  
3 1 only included patients who received inpatient treatment for TB in KKH, potentially missing the  
4  
5 2 less severe group who received outpatient therapy.  
6  
7  
8  
9 3  
10  
11  
12 4  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Confidential: For Review Only

## 1 CONCLUSION

2 Extra-pulmonary TB is more common in the younger age group and is associated with lower  
3 recovery rate, higher rates of sequelae and mortality. As TB culture has a long turnover time,  
4 treatment for TB should not be delayed if other factors are strongly suggestive of TB. Clinicians  
5 should have a high index of suspicion for EPTB and should pay special attention to the younger  
6 age group.

## 1 **What is already known on this topic**

2  
3  
4  
5  
6 2 Diagnosis of pediatric TB can be challenging as presentation ranges from non-specific symptoms  
7  
8 3 to severe clinical presentation. The proportion of EPTB has increased in the adult population.  
9  
10 4 However, little is known about the global impact of pediatric EPTB.  
11  
12  
13  
14 5

## 6 **What this study adds**

7  
8 7 Locally, this study aims to re-examine the clinical profile and treatment outcomes of pediatric  
9  
10 8 TB in Singapore. Globally, this study aims to add new information to the differences between  
11  
12 9 pediatric PTB and EPTB. Extra-pulmonary TB is more common in the younger age group and is  
13  
14 10 associated with lower recovery rate, higher rates of sequelae and mortality  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34 12  
35  
36 13  
37  
38 14  
39  
40  
41 15  
42  
43 16  
44  
45 17  
46  
47  
48 18  
49  
50 19  
51  
52 20  
53  
54  
55 21  
56  
57  
58  
59  
60

## 1 REFERENCES

1. Ministry of Health, Singapore. Communicable Diseases Surveillance in Singapore 2016, Singapore. p. 103 - 15.
2. Yang Z, Kong Y, Wilson F, Foxman B, Fowler AH, Marrs CF, et al. Identification of risk factors for extrapulmonary tuberculosis. *Clin Infect Dis*. 2004;38(2):199-205.
3. Gonzalez OY, Adams G, Teeter LD, Bui TT, Musser JM, Graviss EA. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. *Int J Tuberc Lung Dis*. 2003;7(12):1178-85.
4. World Health Organization. Global Tuberculosis Report 2015. Geneva; 2015. .
5. Sandgren A, Hollo V, van der Werf MJ. Extrapulmonary tuberculosis in the European Union and European Economic Area, 2002 to 2011. *Euro Surveill*. 2013;18(12).
6. Santiago-García B, Blázquez-Gamero D, Baquero-Artigao F, Ruíz-Contreras J, Bellón JM, Muñoz-Fernández MA, et al. Pediatric Extrapulmonary Tuberculosis: Clinical Spectrum, Risk Factors and Diagnostic Challenges in a Low Prevalence Region. *Pediatr Infect Dis J*. 2016;35(11):1175-81.
7. PAUL FM. Tuberculosis in B.C.G. vaccinated children in Singapore. *Arch Dis Child*. 1961;36:530-6.
8. Paul F. Tuberculosis meningitis in children in the Department of Paediatrics over a ten-year period. *Singapore Med J*. 1967;8(2):102-10.
9. Moore D, Hani C, H Hospital B, Schaaf S, Marais B, Moore D, et al. Childhood tuberculosis guidelines of the Southern African Society for Paediatric Infectious Diseases (SASPID)2009.
10. Chee CB, Gan SH, Khinmar KW, Barkham TM, Koh CK, Liang S, et al. Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. *J Clin Microbiol*. 2008;46(6):1935-40.
11. Chan DS, Choy MY, Wang S, Sng LH. An evaluation of the recovery of mycobacteria from urine specimens using the automated Mycobacteria Growth Indicator Tube system (BACTEC MGIT 960). *J Med Microbiol*. 2008;57(Pt 10):1220-2.
12. Wu X-R, Yin Q-Q, Jiao A-X, Xu B-P, Sun L, Jiao W-W, et al. Pediatric Tuberculosis at Beijing Children's Hospital: 2002–2010. *Pediatrics*. 2012;130(6):e1433.
13. Moyo S, Verver S, Mahomed H, Hawkridge A, Kibel M, Hatherill M, et al. Age-related tuberculosis incidence and severity in children under 5 years of age in Cape Town, South Africa. *Int J Tuberc Lung Dis*. 2010;14(2):149-54.
14. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric tuberculosis. *Lancet Infect Dis*. 2008;8(8):498-510.
15. Chew CH, Hu PY. BCG programme in the Republic of Singapore. *Singapore Med J*. 1974;15(4):241-5.
16. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. *JAMA*. 1994;271(9):698-702.
17. Marais BJ, Obihara CC, Gie RP, Schaaf HS, Hesselting AC, Lombard C, et al. The prevalence of symptoms associated with pulmonary tuberculosis in randomly selected children from a high burden community. *Arch Dis Child*. 2005;90(11):1166-70.
18. Marais BJ, Gie RP, Hesselting AC, Schaaf HS, Lombard C, Enarson DA, et al. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. *Pediatrics*. 2006;118(5):e1350-9.
19. Hesselting AC, Schaaf HS, Gie RP, Starke JR, Beyers N. A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. *Int J Tuberc Lung Dis*. 2002;6(12):1038-45.

- 1  
2  
3 1 20. Swaminathan S, Datta M, Radhamani MP, Mathew S, Reetha AM, Rajajee S, et al. A profile of  
4 2 bacteriologically confirmed pulmonary tuberculosis in children. *Indian Pediatr.* 2008;45(9):743-7.  
5 3 21. Hoog AH, Meme HK, van Deutekom H, Mithika AM, Olunga C, Onyino F, et al. High sensitivity of  
6 4 chest radiograph reading by clinical officers in a tuberculosis prevalence survey. *Int J Tuberc Lung Dis.*  
7 5 2011;15(10):1308-14.  
8 6 22. Piccasso R, Paparo F, Garlaschi G. Diagnostic accuracy of chest radiography for the diagnosis of  
9 7 tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review. *J Rheumatol*  
10 8 *Suppl.* 2014;91:32-40.  
11 9 23. Winston CA, Menzies HJ. Pediatric and Adolescent Tuberculosis in the United States, 2008–2010.  
12 10 *Pediatrics.* 2012;130(6):e1425.  
13 11 24. Bergamini BM, Losi M, Vaienti F, D'Amico R, Meccugni B, Meacci M, et al. Performance of  
14 12 commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents.  
15 13 *Pediatrics.* 2009;123(3):e419-24.  
16 14 25. Connell T, Tebruegge M, Ritz N, Curtis N. Interferon-gamma release assays for the diagnosis of  
17 15 tuberculosis. *Pediatr Infect Dis J.* 2009;28(8):758-9.  
18 16 26. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis  
19 17 infection: areas of uncertainty and recommendations for research. *Ann Intern Med.* 2007;146(5):340-54.  
20 18 27. Perez-Velez CM, Marais BJ. Tuberculosis in Children. *New England Journal of Medicine.*  
21 19 2012;367(4):348-61.  
22  
23  
24  
25 20  
26  
27 21  
28  
29 22  
30  
31 23  
32  
33  
34 24  
35  
36 25  
37  
38 26  
39  
40  
41 27  
42  
43 28  
44  
45  
46 29  
47  
48 30  
49  
50 31  
51  
52 32  
53  
54  
55  
56  
57  
58  
59  
60

1 **Table 1. Comparison of Pulmonary and Extra-pulmonary TB**

	Pulmonary N= 49 (%)	Extra-pulmonary N= 26 (%)	P value
Median age (years)	10.1 (IQR 3.5, 13.5)	5.1 (IQR 1.2, 10.2)	0.03
Gender			0.82
Males	25 (51)	14 (54)	
Females	24 (49)	12 (46)	
Nationality			0.21
Singapore residents	37 (76)	16 (62)	
Non-Singapore residents	12 (24)	10 (38)	
Received BCG vaccine	41 (89)	19 (76)	0.14
Comorbidities			<0.01
Immunodeficient	3 (6)	9 (35)	
Not immunodeficient	46 (94)	17 (65)	
Contact history			0.06
Positive contact	22 (45)	6 (23)	
No contact history	27 (55)	20 (77)	
Symptoms			
Significant fever	9 (19)	11 (48)	0.01
Significant cough	22 (51)	3 (14)	<0.01
Significant weight loss	18 (39)	6 (27)	0.34
Median weight loss (%body weight)	10.6 (IQR 5.8, 20.0)	16.3 (IQR 13.6, 40.6)	0.29
Fatigue	2 (4)	2 (8)	0.60
Lymphadenopathy	2 (4)	8 (31)	<0.01
≥ 2 symptoms stated above	14 (29)	5 (23)	0.61
No symptom stated above	22 (45)	11 (42)	0.83
Hematological results			
Median hemoglobin (g/dL)	12.0 (IQR 10.5, 13.9)	11.2 (IQR 10.2, 11.9)	0.03
Median white blood cells (x10 <sup>9</sup> /L)	11.2 (IQR 7.5, 15.6)	10.2 (IQR 7.6, 12.0)	0.15
Median Platelet (x10 <sup>9</sup> /L)	376.5 (IQR 281.5, 451.0)	377.0 (IQR 339.5, 507.0)	0.38
Median ESR (mm/hr)	40.0 (IQR 15.0, 85.0)	34.0 (IQR 19.0, 54.5)	0.61
Median CRP (mg/L)	36.0 (IQR 16.5, 84.4)	32.4 (IQR 8.6, 69.3)	0.43
Immunological results			
Positive TST	20 (41)	6 (23)	0.10
Positive IGRA	20 (41)	12 (46)	0.80
Microbiological			0.10
Microbiologically proven	26 (53)	19 (73)	
Not microbiologically proven	23 (47)	7 (27)	
Microbiological results			
≥ 1 site/sample positive AFB smear	13 (27)	7 (28)	0.89
≥ 1 site/sample positive AFB culture	24 (49)	15 (58)	0.47
≥ 1 site/sample positive TB PCR	14 (40)	12 (60)	0.15
Abnormal CXR	41 (84)	10 (39)	<0.01
Treatment outcome			
Recovered	28 (57)	7 (27)	0.01
Death	2 (4)	4 (15)	0.17
Relapsed	1 (2)	1 (4)	-
Sequelae	10 (20)	9 (35)	0.18
Lost to follow up	8 (16)	3 (12)	0.73
Still completing treatment	0 (0)	2 (8)	-
Median duration of treatment (months)	6.0 (IQR 6.0, 9.0)	12.0 (IQR 9.0, 12.0)	<0.01

2



1 **Table 2. Types of immunodeficiencies in Pulmonary and Extra-pulmonary TB**

Types of immunodeficiencies	Pulmonary N= 49 (%)	Extra-pulmonary N= 26 (%)
HIV	2 (4)	2 (8)
Malignancy	0 (0)	2 <sup>b</sup> (8)
Immunodeficiency	0 (0)	2 <sup>c</sup> (8)
Others	1 <sup>a</sup> (2)	3 <sup>d</sup> (12)

2 <sup>a</sup> Epstein Barr Virus-related haemophagocytic lymphohistiocytosis

3 <sup>b</sup> 1 Medulloblastoma on chemotherapy, 1 Neuroblastoma on chemotherapy

4 <sup>c</sup> Severe combined immunodeficiency

5 <sup>d</sup> 1 Crohn's disease on immunosuppressant, 1 Juvenile idiopathic arthritis on biologics, 1 Mendelian susceptibility to  
6 mycobacterial disease

8 **Table 3. Outcomes of Pulmonary and Extra-pulmonary TB**

	Pulmonary N= 49 (%)	Extra-pulmonary N= 26 (%)
Types of sequelae 10 PTB (20%) 9 EPTB (35%)	3 (6) Bronchus compression 3 (6) Bronchiectasis 2 (4) Restrictive lung diseases 2 (4) Complications from underlying condition	1 (4) Intestinal perforation 1 (4) Kyphosis 1 (4) CNS infarct 2 (8) Seizures 2 (8) Developmental delay 2 (8) Complications from underlying condition
Reasons for mortality 2 PTB (4%) 4 EPTB (15%)	1 (2) Septic shock 1 (2) Pulmonary haemorrhage	2 (8) Septic shock 1 (4) Severe cerebral edema 1 (4) Underlying malignancy
Reasons for relapse 1 PTB (2%) 1 EPTB (4%)	1 (2) Reactivation of pulmonary TB with TB pericarditis (cause unknown)	1 (4) Recurrent TB lymphadenitis (cause unknown)

9

10

## BMJ Paediatrics Open

### Paediatric Tuberculosis in Singapore - A Retrospective Review

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2018-000308.R2
Article Type:	Original article
Date Submitted by the Author:	05-Aug-2018
Complete List of Authors:	Loh, Sin Wee; KK Women's and Children's Hospital, Department of Pediatrics Thoon , Koh Cheng ; KK Women's and Children's Hospital, Infectious Disease Service; National University Singapore Yong Loo Lin School of Medicine Tan , Natalie Woon Hui ; KK Women's and Children's Hospital, Infectious Disease Service; National University Singapore Yong Loo Lin School of Medicine Li , Jiahui; KK Women's and Children's Hospital, Infectious Disease Service Chong , Chia Yin ; KK Women's and Children's Hospital, Infectious Disease Service; National University Singapore Yong Loo Lin School of Medicine
Keywords:	Infectious Diseases

SCHOLARONE™  
Manuscripts

1  
2  
3 **1 PAEDIATRIC TUBERCULOSIS IN SINGAPORE – A RETROSPECTIVE**  
4  
5  
6 **2 REVIEW**  
7

8  
9 **3 SW Loh<sup>1</sup>, KC Thoon<sup>2,3,4</sup>, NWH Tan<sup>2,3,4,5</sup>, JH Li<sup>2</sup>, CY Chong<sup>2,3,4,5</sup>**  
10

11  
12 <sup>1</sup> Department of Pediatrics, KK Women's and Children's Hospital, Singapore  
13

14  
15 <sup>2</sup> Infectious Disease Service, Department of Pediatrics, KK Women's and Children's Hospital,  
16  
17  
18 Singapore  
19

20  
21 <sup>3</sup> Yong Loo Lin School of Medicine, National University of Singapore, Singapore  
22

23  
24 <sup>4</sup> Duke-National University of Singapore Medical School, Singapore  
25

26  
27 <sup>5</sup> Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore  
28  
29

30  
31 **10 Corresponding author:**  
32

33  
34 Sin Wee Loh, MB BCh BAO(Ireland), MRCPCH(UK), MMED(Singapore)  
35

36  
37 Department of Pediatrics  
38

39  
40 KK Women's and Children's Hospital  
41

42  
43 100 Bukit Timah Road, Singapore 229899  
44

45  
46 Email: sinwee.loh@mohh.com.sg  
47

48  
49 Telephone: +65 96188260  
50  
51

52  
53 17  
54  
55  
56  
57  
58  
59  
60

## 1 **Acknowledgements**

2 SW Loh, KC Thoon and CY Chong were involved in the design of the study. SW Loh was in  
3 charge of acquisition of data, interpretation of data and drafting of the manuscript. KC Thoon,  
4 NWH Tan, JH Li and CY Chong were involved in revising and approval of the final manuscript.  
5 CY Chong provided mentorship throughout the project.

6 Conflicts of interest: None

## 1 ABSTRACT

2 **Background:** Tuberculosis (TB) is a major cause of mortality and morbidity in the world. Each  
3 case represents on-going transmission and has a significant public health burden. We aim to (i)  
4 examine the clinical profile of paediatric TB and (ii) compare pulmonary TB (PTB) with extra-  
5 pulmonary TB (EPTB) in Singapore.

6 **Methods:** Retrospective study of patients admitted to KK Women's and Children's Hospital,  
7 Singapore, from January 2008 to September 2017 for active TB disease. We compared clinical  
8 characteristics and outcomes of patients with PTB and EPTB.

9 **Results:** Seventy-five patients were diagnosed as active TB; 65% PTB and 35% EPTB. Patients  
10 with EPTB were more likely to be younger [Median age 5.1 (interquartile range (IQR) 1.2, 10.2)  
11 vs 10.1 (IQR 3.5, 13.5) years], immunodeficient (35% vs 6%), had lower haemoglobin count  
12 [Median 11.5 (IQR 10.2, 11.9) vs 12.0 (IQR 10.5, 13.9) g/dL], lower recovery rate (27% vs  
13 57%) and required longer duration of treatment [Median 12 (IQR 9, 12) vs 6 (IQR 6,9) months].  
14 Common clinical presentations of both PTB and EPTB were significant fever (27%), cough  
15 (33%) and weight loss (32%). Overall mortality was 8% with septic shock responsible for 3 of  
16 the 6 deaths.

17 **Conclusion:** Extra-pulmonary TB is more common in the younger age group and is associated  
18 with lower recovery rate and higher sequelae rate.

19

20

21

## 1 INTRODUCTION

2 Tuberculosis (TB) remains a major cause of morbidity and mortality in the world. Following the  
3 introduction of Singapore Tuberculosis Elimination Programme in 1997; the incidence of TB  
4 declined from 57 per 100,000 residents in the 1990s to a low of 35 per 100,000 residents in 2007.  
5 In 2016, the incidence rate of TB was 38.7 per 100,000 residents in Singapore; children below 19  
6 years old contributed only 2.1% of the total TB population. The majority (84%) of cases had  
7 pulmonary TB (PTB) with or without extra-pulmonary involvement, while the remainder (17%)  
8 had exclusively extra-pulmonary TB (EPTB) (1).

9 The presentation of TB in children can range from non-specific symptoms to severe clinical  
10 presentation; which makes diagnosis challenging. Although PTB is the most common  
11 involvement, all other organs can be involved as well (2, 3). Globally in 2014, almost 10 million  
12 people developed TB, of which EPTB represented almost 15% of the overall TB (4). In adults,  
13 proportion of EPTB to PTB has increased due to a decrease in PTB rates (5). However, little is  
14 known of the global impact of pediatric EPTB due to difficulties in pediatric TB case detection  
15 and low notification rates (6). The last published review of pediatric TB in Singapore was by  
16 Freda M. Paul in 1967, which focused on the fatality of tuberculous meningitis. With the  
17 changing demographics in Singapore, a new review of pediatric TB is needed (7, 8). The aims of  
18 this study were to (i) examine the clinical profile and treatment outcomes of pediatric TB and (ii)  
19 compare PTB with EPTB.

## 1     **METHODS**

### 2     **Setting**

3     Kandang Kerbau (KK) Women's and Children's Hospital (KKH) is the largest tertiary pediatric  
4     hospital in Singapore with approximately 350 pediatric beds, and accounts for 54% of pediatric  
5     admissions nationally (based on market trends, Corporate communications, KKH). We collected  
6     data of all patients who were admitted for TB work-up in KKH from January 2008 to September  
7     2017. Approval was obtained from the centralized institution review board of Singhealth  
8     Research.

### 9     **Patient identification and data collection**

10    A patient list with the code tuberculosis was generated using International Classification of  
11    Disease [ICD9CM or ICD10AM (from 2012 onwards)]. Patients who were treated for active TB  
12    were included, latent TB cases were excluded. Data pertaining to demographic profile, clinical  
13    presentation, investigations and treatment of selected cases were collected from case notes,  
14    electronic records and the infectious disease database.

### 15    **Case definitions**

16    Both microbiologically proven cases and non- microbiologically proven cases were included.  
17    Microbiologically proven cases were defined as those with positive TB culture and/or TB  
18    polymerase chain reaction (PCR). Non-microbiologically proven cases were defined as those  
19    with negative TB culture or PCR but positive TB smear, tuberculin skin test, interferon gamma  
20    release assay (IGRA) in the presence of clinical diagnosis of TB or suggestive chest X-ray  
21    (CXR). EPTB was defined as any active TB case involving organs other than lungs and pleural.

1 Multi-organ TB was defined as active TB involving 2 or more organs and was considered EPTB.

2 CNS TB (subset of EPTB) was defined as TB meningitis or meningoencephalitis.

3 Close contact was defined as living in the same household or in frequent contact with smear  
4 positive pulmonary TB case. Immunodeficiency was either primary immune disorders or  
5 secondary to an underlying disease or immunosuppressive drugs. Definitions of symptoms were  
6 adapted from the South African Guidelines 2013 (9);

- 7 • Significant cough was defined as cough duration of  $\geq 14$  days
- 8 • Significant fever was defined as temperature  $\geq 38^{\circ}\text{C}$  for  $\geq 14$  days
- 9 • Significant weight loss was defined as  $\geq 1\text{kg}$  for  $\geq 1$  month. Weight loss was  
10 further expressed as a percentage of body weight at diagnosis.
- 11 • Fatigue: Patient's or parents' complaint of reduced playfulness or lethargy

12 In our center, T-SPOT.TB assay (Oxford Immunotec, Abingdon, United Kingdom) is the  
13 preferred type of IGRA used for children  $\geq 2$  years old because of the lower rate of indeterminate  
14 results compared to QuantiFERON-TB Gold and QuantiFERON-TB In-tube (10). Tuberculin  
15 skin test (TST) might be performed when T-spot was not available (i.e. out of office hours).  
16 Positive TST was defined as reading of  $\geq 10\text{mm}$  at 48 hours. All patients had CXR performed  
17 and reported by in-house radiologists. All our patients had microbiological investigations.  
18 Consecutive fluid specimens were sent for acid-fast bacilli (AFB) smear and culture. The TB  
19 culture method was by the automated MGIT960 system for liquid growth and Lowenstein Jensen  
20 slants for solid growth (10, 11). Multi-drug-resistant TB (MDR-TB) was defined as resistance to  
21 both rifampicin and isoniazid.

## 22 **Statistical analysis**



1  
2  
3 1 Analysis was carried out using SPSS version 19 (IBM, Armonk, New York, USA). Categorical  
4  
5 2 data were expressed as counts and percentages whereas continuous data were expressed as  
6  
7 3 median and interquartile ranges (IQR). Differences between categorical data were analysed by  
8  
9 4 chi-square tests or Fisher's exact test when cell sizes were less than 5. Differences between  
10  
11 5 continuous data were analysed by Mann-Whitney test. All statistical tests were 2-tailed and a P  
12  
13 6 value of  $<0.05$  was statistically significant.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 RESULTS

2 Seventy-five patients were included; 49 (65%) had PTB and 26 (35%) had EPTB. Further  
3 breakdown of EPTB: 5 lymphatic; 7 central nervous system (CNS); 1 pericardial, 2 gastro-  
4 intestinal; 1 eye, 2 musculoskeletal and 8 multi-organ TB. All cases of CNS TB were TB  
5 meningitis. Of the multi-organ TB: 2 had involvement of pulmonary and CNS, 1 patient each  
6 had involvement of CNS and lymphatics; GIT and MSK; pulmonary and GIT; pulmonary and  
7 lymphatics; GIT, lymphatics and MSK; GIT and pulmonary.

8 Table 1 describes the differences between PTB and EPTB. Patients with EPTB were younger  
9 [Median age 5.05 years (IQR 1.23, 10.23) vs 10.10 years (IQR 3.47, 13.45),  $p=0.03$ ], more likely  
10 to be immunodeficient (35% vs 6%,  $p<0.01$ ) and had lower hemoglobin (Hb) level [Median Hb  
11 level 11.15 g/dL (IQR 10.23, 11.90) vs 12.00 g/dL (IQR 10.50, 13.85),  $p=0.01$ ]. Common  
12 clinical presentations of both PTB and EPTB were significant fever (27%), cough (33%) and  
13 weight loss (32%). However, only 20 (27%) of our patients presented with  $\geq 2$  significant  
14 symptoms. Patients with PTB were more likely to have significant cough whereas those with  
15 EPTB were more likely to present with significant fever and/or lymphadenopathy (Table 1).  
16 Twenty-eight patients (37%) had positive TB contact; 26 household contacts and 2 school  
17 contacts. Only 4 (5%) patients had  $\geq 2$  significant symptoms and positive contact history.

18 Abnormal CXR was found in 51 patients (68%) with the following changes: pulmonary  
19 infiltrates (n=24, 32%), hilar adenopathy (n=7, 9%), miliary (n=4, 5%), lobar collapse (n=3, 4%),  
20 pleural changes (n=2, 3%), cavitation (n=2, 3%), widened mediastinum (n=1, 1%) and  
21 combination of findings (n=8, 11%). Patients with PTB were more likely to have abnormal CXR  
22 compared to those with EPTB (84% vs 39%,  $p<0.01$ ).

1 More than half of PTB and EPTB had microbiologically proven disease (53% and 73%  
2 respectively). T-Spot was performed in 41 (55%) patients: 32 (78%) positive, 6 (15%) negative  
3 and 3 (7%) indeterminate. TST was performed in 31 patients (41%): 26 (84%) positive with  
4 median reading was 14.5 mm (IQR 11.0, 20.0). However, there were no significant differences in  
5 the percentage of positive smear, culture, PCR, TST or T-Spot disease between PTB and EPTB.  
6 There were no cases of MDR-TB in our cohort.

7 All patients received isoniazid and rifampicin with pyrazinamide and/or ethambutol. Patients  
8 with EPTB needed longer duration of treatment compared to those with PTB [Median 12 (IQR 9,  
9 12) vs 6 (IQR 6, 9) months,  $p < 0.01$ ]. Twelve (16.0%) patients were immunodeficient; Table 2  
10 describes the types of immunodeficiencies in both PTB and EPTB patients Patients who were  
11 immunodeficient were also treated for a longer period compared to immunocompetent patients  
12 [Median 12 (IQR 10, 12) vs 6 (IQR 6, 9) months,  $p < 0.01$ ].

13 Overall mortality rate was 8.0%. Mortality rate of PTB and EPTB was 4% and 15% respectively.  
14 Event-free survival in PTB patients compared to EPTB was 57% vs 27% ( $p = 0.01$ ). Of the 4  
15 deaths in EPTB, 2 patients (50%) had TB meningitis. Mortality rate of TB meningitis was 29%.  
16 Septic shock accounted for 3 out of 6 deaths in both PTB and EPTB. Table 3 describes the  
17 details of sequelae, mortality and relapse cases of PTB and EPTB.

## 1 DISCUSSION

2 Our study compares the demographics, clinical spectrum, investigation results and outcomes of  
3 PTB and EPTB.

4 The median age of patients with EPTB was significantly younger than PTB [Median age 5.05 vs  
5 10.10 years,  $p=0.03$ ], similar to another paediatric TB study (12). EPTB had lower recovery rate,  
6 high mortality, relapse and sequelae rates compared to PTB. Similar to other studies, this implied  
7 that younger children had higher risk of serious TB (13, 14). The mortality of TB meningitis  
8 from our review had decreased drastically from a peak of 60% in 1955 (7, 8). Mass BCG  
9 vaccination campaign, implemented in 1957, was one of the key interventions that led to a  
10 marked decrease in TB mortality rates, especially EPTB and for children < 5 years old (15, 16).

11 A retrospective pediatric study in China showed that EPTB was more prevalent in the BCG  
12 unvaccinated group (59% vs 41%,  $p=0.05$ ); our small study failed to show any significant  
13 difference (12). This finding suggests that children who received BCG vaccination have less  
14 chance of contracting EPTB.

15 Children with TB rarely present with classical symptoms as seen in a survey from a high burden  
16 community (17). This is similar to our study in which only 27% of patients presented with  $\geq 2$   
17 out of 5 significant symptoms stated by South African Society for Pediatric Infectious Diseases  
18 (9). Marais et al stated that the index of suspicion should be increased when symptoms such as  
19 prolonged cough of more than 2 weeks, significant weight loss and fatigue exist together with  
20 positive TB contact (18). Four (5%) of our patients with TB had  $\geq 2$  significant symptoms and  
21 positive contact history. Nevertheless, available scoring systems should not be used for  
22 predicting pediatric TB infection as they lack sensitivity and specificity (19).

1  
2  
3 1 Sixty-eight percent of patients had abnormal CXR, which was higher than a large-scale  
4  
5 2 multicenter center study conducted in India (20). This can be explained by significant variation  
6  
7 3 between radiologists when interpreting pediatric CXR (21). Moreover, CXR had a high  
8  
9 4 sensitivity but low specificity for detecting active TB as many radiological changes seen in TB  
10  
11 5 could be present in other infections (22).

12  
13  
14  
15 6 A positive microbiological culture remains the gold standard for diagnosis of active TB but is  
16  
17 7 often limited by the prolonged turnover time. In this study, the percentage of patients with  
18  
19 8 eventual positive TB culture (49.0% and 57.5%) was more than those with  $\geq 1$  positive AFB  
20  
21 9 smear (26.5% and 28.0%) in both the PTB and EPTB group, which could lead to a delay in  
22  
23 10 identification and treatment of active TB disease. Our higher TB culture rates compared to  
24  
25 11 15.7% in China and 34% in USA could be due to more aggressive sampling methods or different  
26  
27 12 culture methods (12, 23).

28  
29  
30  
31  
32 13 Immunological investigations such as TST and IGRA can aid in the diagnosis of TB but each has  
33  
34 14 its own limitations. In children  $< 4$  years old, T-Spot is preferred as it has lower rate of  
35  
36 15 indeterminate results compared to QuantiFERON-TB test (24). While IGRA and TST are good  
37  
38 16 predictors of latent TB infection, their sensitivity for active TB infection are much more limited  
39  
40 17 (25, 26). Regardless of TST or IGRA results, treatment for TB should not be delayed if factors  
41  
42 18 are strongly suggestive of TB (contact history, radiologic and microbiologic) (27).

43  
44  
45  
46  
47 19 The limitations of this study were the small sample size and its retrospective nature. It was not  
48  
49 20 powered to correlate the effect of age, gender, and symptoms to laboratory results. This study  
50  
51 21 only included patients who received inpatient treatment for TB in KKH, potentially missing the  
52  
53 22 less severe group who received outpatient therapy.

54  
55  
56  
57 23

1  
2  
3 **1 CONCLUSION**  
4

5  
6 2 Extra-pulmonary TB is more common in the younger age group and is associated with lower  
7  
8 3 recovery rate and higher sequelae rate. As TB culture has a long turnover time, treatment for TB  
9  
10 4 should not be delayed if other factors are strongly suggestive of TB. Clinicians should have a  
11  
12 5 high index of suspicion for EPTB and should pay special attention to the younger age group.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **1 What is already known on this topic**  
4  
5

6 2 Diagnosis of pediatric TB can be challenging as presentation ranges from non-specific symptoms  
7  
8 3 to severe clinical presentation. The proportion of EPTB has increased in the adult population.  
9  
10 4 However, little is known about the global impact of pediatric EPTB.  
11  
12  
13  
14  
15  
16

17 **6 What this study adds**  
18  
19

20 7 Common clinical presentations involving a third of patients with both PTB and EPTB were  
21  
22 8 significant fever, cough and weight loss. Patients with EPTB were more likely to be  
23  
24 9 immunodeficient. Extra-pulmonary TB is more common in the younger age group and is  
25  
26  
27 10 associated with lower recovery rate and higher sequelae rate.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 REFERENCES

1. Ministry of Health, Singapore. Communicable Diseases Surveillance in Singapore 2016, Singapore. p. 103 - 15.
2. Yang Z, Kong Y, Wilson F, Foxman B, Fowler AH, Marrs CF, et al. Identification of risk factors for extrapulmonary tuberculosis. *Clin Infect Dis*. 2004;38(2):199-205.
3. Gonzalez OY, Adams G, Teeter LD, Bui TT, Musser JM, Graviss EA. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. *Int J Tuberc Lung Dis*. 2003;7(12):1178-85.
4. World Health Organization. Global Tuberculosis Report 2015. Geneva; 2015. .
5. Sandgren A, Hollo V, van der Werf MJ. Extrapulmonary tuberculosis in the European Union and European Economic Area, 2002 to 2011. *Euro Surveill*. 2013;18(12).
6. Santiago-García B, Blázquez-Gamero D, Baquero-Artigao F, Ruíz-Contreras J, Bellón JM, Muñoz-Fernández MA, et al. Pediatric Extrapulmonary Tuberculosis: Clinical Spectrum, Risk Factors and Diagnostic Challenges in a Low Prevalence Region. *Pediatr Infect Dis J*. 2016;35(11):1175-81.
7. PAUL FM. Tuberculosis in B.C.G. vaccinated children in Singapore. *Arch Dis Child*. 1961;36:530-6.
8. Paul F. Tuberculosis meningitis in children in the Department of Paediatrics over a ten-year period. *Singapore Med J*. 1967;8(2):102-10.
9. Moore D, Hani C, H Hospital B, Schaaf S, Marais B, Moore D, et al. Childhood tuberculosis guidelines of the Southern African Society for Paediatric Infectious Diseases (SASPID)2009.
10. Chee CB, Gan SH, Khinmar KW, Barkham TM, Koh CK, Liang S, et al. Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. *J Clin Microbiol*. 2008;46(6):1935-40.
11. Chan DS, Choy MY, Wang S, Sng LH. An evaluation of the recovery of mycobacteria from urine specimens using the automated Mycobacteria Growth Indicator Tube system (BACTEC MGIT 960). *J Med Microbiol*. 2008;57(Pt 10):1220-2.
12. Wu X-R, Yin Q-Q, Jiao A-X, Xu B-P, Sun L, Jiao W-W, et al. Pediatric Tuberculosis at Beijing Children's Hospital: 2002–2010. *Pediatrics*. 2012;130(6):e1433.
13. Moyo S, Verver S, Mahomed H, Hawkridge A, Kibel M, Hatherill M, et al. Age-related tuberculosis incidence and severity in children under 5 years of age in Cape Town, South Africa. *Int J Tuberc Lung Dis*. 2010;14(2):149-54.
14. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric tuberculosis. *Lancet Infect Dis*. 2008;8(8):498-510.
15. Chew CH, Hu PY. BCG programme in the Republic of Singapore. *Singapore Med J*. 1974;15(4):241-5.
16. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. *JAMA*. 1994;271(9):698-702.
17. Marais BJ, Obihara CC, Gie RP, Schaaf HS, Hesselning AC, Lombard C, et al. The prevalence of symptoms associated with pulmonary tuberculosis in randomly selected children from a high burden community. *Arch Dis Child*. 2005;90(11):1166-70.
18. Marais BJ, Gie RP, Hesselning AC, Schaaf HS, Lombard C, Enarson DA, et al. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. *Pediatrics*. 2006;118(5):e1350-9.
19. Hesselning AC, Schaaf HS, Gie RP, Starke JR, Beyers N. A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. *Int J Tuberc Lung Dis*. 2002;6(12):1038-45.



- 1  
2  
3 1 20. Swaminathan S, Datta M, Radhamani MP, Mathew S, Reetha AM, Rajajee S, et al. A profile of  
4 2 bacteriologically confirmed pulmonary tuberculosis in children. *Indian Pediatr.* 2008;45(9):743-7.  
5 3 21. Hoog AH, Meme HK, van Deutekom H, Mithika AM, Olunga C, Onyino F, et al. High sensitivity of  
6 4 chest radiograph reading by clinical officers in a tuberculosis prevalence survey. *Int J Tuberc Lung Dis.*  
7 5 2011;15(10):1308-14.  
8 6 22. Piccasso R, Paparo F, Garlaschi G. Diagnostic accuracy of chest radiography for the diagnosis of  
9 7 tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review. *J Rheumatol*  
10 8 *Suppl.* 2014;91:32-40.  
11 9 23. Winston CA, Menzies HJ. Pediatric and Adolescent Tuberculosis in the United States, 2008–2010.  
12 10 *Pediatrics.* 2012;130(6):e1425.  
13 11 24. Bergamini BM, Losi M, Vaienti F, D'Amico R, Meccugni B, Meacci M, et al. Performance of  
14 12 commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents.  
15 13 *Pediatrics.* 2009;123(3):e419-24.  
16 14 25. Connell T, Tebruegge M, Ritz N, Curtis N. Interferon-gamma release assays for the diagnosis of  
17 15 tuberculosis. *Pediatr Infect Dis J.* 2009;28(8):758-9.  
18 16 26. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis  
19 17 infection: areas of uncertainty and recommendations for research. *Ann Intern Med.* 2007;146(5):340-54.  
20 18 27. Perez-Velez CM, Marais BJ. Tuberculosis in Children. *New England Journal of Medicine.*  
21 19 2012;367(4):348-61.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 **Table 1. Comparison of Pulmonary and Extra-pulmonary TB**

	Pulmonary N= 49 (%)	Extra-pulmonary N= 26 (%)	P value
Median age (years)	10.1 (IQR 3.5, 13.5)	5.1 (IQR 1.2, 10.2)	0.03
Gender			0.82
Males	25 (51)	14 (54)	
Females	24 (49)	12 (46)	
Nationality			0.21
Singapore residents	37 (76)	16 (62)	
Non-Singapore residents	12 (24)	10 (38)	
Received BCG vaccine	41 (89)	19 (76)	0.14
Comorbidities			<0.01
Immunodeficient	3 (6)	9 (35)	
Not immunodeficient	46 (94)	17 (65)	
Contact history			0.06
Positive contact	22 (45)	6 (23)	
No contact history	27 (55)	20 (77)	
Symptoms			
Significant fever	9 (19)	11 (48)	0.01
Significant cough	22 (51)	3 (14)	<0.01
Significant weight loss	18 (39)	6 (27)	0.34
Median weight loss (%body weight)	10.6 (IQR 5.8, 20.0)	16.3 (IQR 13.6, 40.6)	0.29
Fatigue	2 (4)	2 (8)	0.60
Lymphadenopathy	2 (4)	8 (31)	<0.01
≥ 2 symptoms stated above	14 (29)	5 (23)	0.61
No symptom stated above	22 (45)	11 (42)	0.83
Hematological results			
Median hemoglobin (g/dL)	12.0 (IQR 10.5, 13.9)	11.2 (IQR 10.2, 11.9)	0.03
Median white blood cells (x10 <sup>9</sup> /L)	11.2 (IQR 7.5, 15.6)	10.2 (IQR 7.6, 12.0)	0.15
Median Platelet (x10 <sup>9</sup> /L)	376.5 (IQR 281.5, 451.0)	377.0 (IQR 339.5, 507.0)	0.38
Median ESR (mm/hr)	40.0 (IQR 15.0, 85.0)	34.0 (IQR 19.0, 54.5)	0.61
Median CRP (mg/L)	36.0 (IQR 16.5, 84.4)	32.4 (IQR 8.6, 69.3)	0.43
Immunological results			
Positive TST	20 (41)	6 (23)	0.10
Positive IGRA	20 (41)	12 (46)	0.80
Microbiological			0.10
Microbiologically proven	26 (53)	19 (73)	
Not microbiologically proven	23 (47)	7 (27)	
Microbiological results			
≥ 1 site/sample positive AFB smear	13 (27)	7 (28)	0.89
≥ 1 site/sample positive AFB culture	24 (49)	15 (58)	0.47
≥ 1 site/sample positive TB PCR	14 (40)	12 (60)	0.15
Abnormal CXR	41 (84)	10 (39)	<0.01
Treatment outcome			
Recovered	28 (57)	7 (27)	0.01
Death	2 (4)	4 (15)	0.17
Relapsed	1 (2)	1 (4)	-
Sequelae	10 (20)	9 (35)	0.18
Lost to follow up	8 (16)	3 (12)	0.73
Still completing treatment	0 (0)	2 (8)	-
Median duration of treatment (months)	6.0 (IQR 6.0, 9.0)	12.0 (IQR 9.0, 12.0)	<0.01

2

1 **Table 2. Types of immunodeficiencies in Pulmonary and Extra-pulmonary TB**

Types of immunodeficiencies	Pulmonary N= 49 (%)	Extra-pulmonary N= 26 (%)
HIV	2 (4)	2 (8)
Malignancy	0 (0)	2 <sup>b</sup> (8)
Primary immune deficiency	0 (0)	2 <sup>c</sup> (8)
Others	1 <sup>a</sup> (2)	3 <sup>d</sup> (12)

2 <sup>a</sup> Ebstein Barr Virus-related haemophagocytic lymphohistiocytosis

3 <sup>b</sup> 1 Medulloblastoma on chemotherapy, 1 Neuroblastoma on chemotherapy

4 <sup>c</sup> Severe combined immunodeficiency

5 <sup>d</sup> 1 Crohn's disease on immunosuppressant, 1 Juvenile idiopathic arthritis on biologics, 1 Mendelian susceptibility to  
6 mycobacterial disease

8 **Table 3. Outcomes of Pulmonary and Extra-pulmonary TB**

	Pulmonary N = 49		Extrapulmonary N = 26			
		n	%	n	%	
Types of sequelae	Bronchus compression	3	6	Intestinal perforation	1	4
	Bronchiectasis	3	6	Kyphosis	1	4
	Restrictive lung disease	2	4	CNS infarct	1	4
	Complications from underlying condition	2	4	Complications from underlying condition	2	8
Reasons for mortality <sup>a</sup>	Septic shock	1	2	Septic Shock	2	8
	Pulmonary haemorrhage	1	2	Severe Cerebral edema	1	4
				Underlying malignancy	1	4
Reasons for relapse	Reactivation of pulmonary TB with pericarditis (cause unknown)	1	2	Recurrent TB lymphadenitis (cause unknown)	1	4

9 <sup>a</sup> Of 4 EPTB: 2 TB meningitis, 1 pericardial TB, 1 multiorgan TB

# BMJ Paediatrics Open

## Paediatric Tuberculosis in Singapore - A Retrospective Review

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2018-000308.R3
Article Type:	Original article
Date Submitted by the Author:	18-Aug-2018
Complete List of Authors:	Loh, Sin Wee; KK Women's and Children's Hospital, Department of Pediatrics Thoon , Koh Cheng ; KK Women's and Children's Hospital, Infectious Disease Service; National University Singapore Yong Loo Lin School of Medicine Tan , Natalie Woon Hui ; KK Women's and Children's Hospital, Infectious Disease Service; National University Singapore Yong Loo Lin School of Medicine Li , Jiahui; KK Women's and Children's Hospital, Infectious Disease Service Chong , Chia Yin ; KK Women's and Children's Hospital, Infectious Disease Service; National University Singapore Yong Loo Lin School of Medicine
Keywords:	Infectious Diseases

SCHOLARONE™  
Manuscripts

1  
2  
3 **1 PAEDIATRIC TUBERCULOSIS IN SINGAPORE – A RETROSPECTIVE**  
4  
5  
6 **2 REVIEW**  
7

8  
9 **3 SW Loh<sup>1</sup>, KC Thoon<sup>2,3,4</sup>, NWH Tan<sup>2,3,4,5</sup>, JH Li<sup>2</sup>, CY Chong<sup>2,3,4,5</sup>**  
10

11  
12 <sup>1</sup> Department of Pediatrics, KK Women's and Children's Hospital, Singapore  
13

14  
15 <sup>2</sup> Infectious Disease Service, Department of Pediatrics, KK Women's and Children's Hospital,  
16  
17  
18 Singapore  
19

20  
21 <sup>3</sup> Yong Loo Lin School of Medicine, National University of Singapore, Singapore  
22

23  
24 <sup>4</sup> Duke-National University of Singapore Medical School, Singapore  
25

26  
27 <sup>5</sup> Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore  
28  
29

30  
31 **10 Corresponding author:**  
32

33  
34 Sin Wee Loh, MB BCh BAO(Ireland), MRCPCH(UK), MMED(Singapore)  
35

36  
37 Department of Pediatrics  
38

39  
40 KK Women's and Children's Hospital  
41

42  
43 100 Bukit Timah Road, Singapore 229899  
44

45  
46 Email: sinwee.loh@mohh.com.sg  
47

48  
49 Telephone: +65 96188260  
50  
51

52  
53 17  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **1 Acknowledgements**  
4

5 2 SW Loh, KC Thoon and CY Chong were involved in the design of the study. SW Loh was in  
6  
7 3 charge of acquisition of data, interpretation of data and drafting of the manuscript. KC Thoon,  
8  
9 4 NWH Tan, JH Li and CY Chong were involved in revising and approval of the final manuscript.  
10  
11 5 CY Chong provided mentorship throughout the project.  
12  
13

14  
15 6 Conflicts of interest: None  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 ABSTRACT

2 **Background:** Tuberculosis (TB) is a major cause of mortality and morbidity in the world. Each  
3 case represents on-going transmission and has a significant public health burden. We aim to (i)  
4 examine the clinical profile of paediatric TB and (ii) compare pulmonary TB (PTB) with extra-  
5 pulmonary TB (EPTB) in Singapore.

6 **Methods:** Retrospective study of patients admitted to KK Women's and Children's Hospital,  
7 Singapore, from January 2008 to September 2017 for active TB disease. We compared clinical  
8 characteristics and outcomes of patients with PTB and EPTB.

9 **Results:** Seventy-five patients were diagnosed as active TB; 65% PTB and 35% EPTB. Patients  
10 with EPTB were more likely to be younger [Median age 5.1 (interquartile range (IQR) 1.2, 10.2)  
11 vs 10.1 (IQR 3.5, 13.5) years], immunodeficient (35% vs 6%), had lower haemoglobin count  
12 [Median 11.5 (IQR 10.2, 11.9) vs 12.0 (IQR 10.5, 13.9) g/dL], lower recovery rate (27% vs  
13 57%) and required longer duration of treatment [Median 12 (IQR 9, 12) vs 6 (IQR 6,9) months].  
14 Common clinical presentations of both PTB and EPTB were significant fever (27%), cough  
15 (33%) and weight loss (32%). Overall mortality was 8% with septic shock responsible for 3 of  
16 the 6 deaths.

17 **Conclusion:** Extra-pulmonary TB is more common in the younger age group and is associated  
18 with lower recovery rate.

19

20

21

## 1 INTRODUCTION

2 Tuberculosis (TB) remains a major cause of morbidity and mortality in the world. Following the  
3 introduction of Singapore Tuberculosis Elimination Programme in 1997; the incidence of TB  
4 declined from 57 per 100,000 residents in the 1990s to a low of 35 per 100,000 residents in 2007.  
5 In 2016, the incidence rate of TB was 38.7 per 100,000 residents in Singapore; children below 19  
6 years old contributed only 2.1% of the total TB population. The majority (84%) of cases had  
7 pulmonary TB (PTB) with or without extra-pulmonary involvement, while the remainder (17%)  
8 had exclusively extra-pulmonary TB (EPTB) (1).

9 The presentation of TB in children can range from non-specific symptoms to severe clinical  
10 presentation; which makes diagnosis challenging. Although PTB is the most common  
11 involvement, all other organs can be involved as well (2, 3). Globally in 2014, almost 10 million  
12 people developed TB, of which EPTB represented almost 15% of the overall TB (4). In adults,  
13 proportion of EPTB to PTB has increased due to a decrease in PTB rates (5). However, little is  
14 known of the global impact of pediatric EPTB due to difficulties in pediatric TB case detection  
15 and low notification rates (6). The last published review of pediatric TB in Singapore was by  
16 Freda M. Paul in 1967, which focused on the fatality of tuberculous meningitis. With the  
17 changing demographics in Singapore, a new review of pediatric TB is needed (7, 8). The aims of  
18 this study were to (i) examine the clinical profile and treatment outcomes of pediatric TB and (ii)  
19 compare PTB with EPTB.



## 1 **METHODS**

### 2 **Setting**

3 Kandang Kerbau (KK) Women's and Children's Hospital (KKH) is the largest tertiary pediatric  
4 hospital in Singapore with approximately 350 pediatric beds, and accounts for 54% of pediatric  
5 admissions nationally (based on market trends, Corporate communications, KKH). We collected  
6 data of all patients who were admitted for TB work-up in KKH from January 2008 to September  
7 2017. Approval was obtained from the centralized institution review board of Singhealth  
8 Research.

### 9 **Patient identification and data collection**

10 A patient list with the code tuberculosis was generated using International Classification of  
11 Disease [ICD9CM or ICD10AM (from 2012 onwards)]. Patients who were treated for active TB  
12 were included, latent TB cases were excluded. Data pertaining to demographic profile, clinical  
13 presentation, investigations and treatment of selected cases were collected from case notes,  
14 electronic records and the infectious disease database.

### 15 **Case definitions**

16 Both microbiologically proven cases and non- microbiologically proven cases were included.  
17 Microbiologically proven cases were defined as those with positive TB culture and/or TB  
18 polymerase chain reaction (PCR). Non-microbiologically proven cases were defined as those  
19 with negative TB culture or PCR but positive TB smear, tuberculin skin test, interferon gamma  
20 release assay (IGRA) in the presence of clinical diagnosis of TB or suggestive chest X-ray  
21 (CXR). EPTB was defined as any active TB case involving organs other than lungs and pleural.

1 Multi-organ TB was defined as active TB involving 2 or more organs and was considered EPTB.

2 CNS TB (subset of EPTB) was defined as TB meningitis or meningoencephalitis.

3 Close contact was defined as living in the same household or in frequent contact with smear  
4 positive pulmonary TB case. Immunodeficiency was either primary immune disorders or  
5 secondary to an underlying disease or immunosuppressive drugs. Definitions of symptoms were  
6 adapted from the South African Guidelines 2013 (9);

- 7 • Significant cough was defined as cough duration of  $\geq 14$  days
- 8 • Significant fever was defined as temperature  $\geq 38^{\circ}\text{C}$  for  $\geq 14$  days
- 9 • Significant weight loss was defined as  $\geq 1\text{kg}$  for  $\geq 1$  month. Weight loss was  
10 further expressed as a percentage of body weight at diagnosis.
- 11 • Fatigue: Patient's or parents' complaint of reduced playfulness or lethargy

12 In our center, T-SPOT.TB assay (Oxford Immunotec, Abingdon, United Kingdom) is the  
13 preferred type of IGRA used for children  $\geq 2$  years old because of the lower rate of indeterminate  
14 results compared to QuantiFERON-TB Gold and QuantiFERON-TB In-tube (10). Tuberculin  
15 skin test (TST) might be performed when T-spot was not available (i.e. out of office hours).  
16 Positive TST was defined as reading of  $\geq 10\text{mm}$  at 48 hours. All patients had CXR performed  
17 and reported by in-house radiologists. All our patients had microbiological investigations.  
18 Consecutive fluid specimens were sent for acid-fast bacilli (AFB) smear and culture. The TB  
19 culture method was by the automated MGIT960 system for liquid growth and Lowenstein Jensen  
20 slants for solid growth (10, 11). Multi-drug-resistant TB (MDR-TB) was defined as resistance to  
21 both rifampicin and isoniazid.

## 22 **Statistical analysis**

1  
2  
3 1 Analysis was carried out using SPSS version 19 (IBM, Armonk, New York, USA). Categorical  
4  
5 2 data were expressed as counts and percentages whereas continuous data were expressed as  
6  
7 3 median and interquartile ranges (IQR). Differences between categorical data were analysed by  
8  
9 4 chi-square tests or Fisher's exact test when cell sizes were less than 5. Differences between  
10  
11 5 continuous data were analysed by Mann-Whitney test. All statistical tests were 2-tailed and a P  
12  
13 6 value of <0.05 was statistically significant.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 RESULTS

2 Seventy-five patients were included; 49 (65%) had PTB and 26 (35%) had EPTB. Further  
3 breakdown of EPTB: 5 lymphatic; 7 central nervous system (CNS); 1 pericardial, 2 gastro-  
4 intestinal; 1 eye, 2 musculoskeletal and 8 multi-organ TB. All cases of CNS TB were TB  
5 meningitis. Of the multi-organ TB: 2 had involvement of pulmonary and CNS, 1 patient each  
6 had involvement of CNS and lymphatics; GIT and MSK; pulmonary and GIT; pulmonary and  
7 lymphatics; GIT, lymphatics and MSK; GIT and pulmonary.

8 Table 1 describes the differences between PTB and EPTB. Patients with EPTB were younger  
9 [Median age 5.05 years (IQR 1.23, 10.23) vs 10.10 years (IQR 3.47, 13.45),  $p=0.03$ ], more likely  
10 to be immunodeficient (35% vs 6%,  $p<0.01$ ) and had lower hemoglobin (Hb) level [Median Hb  
11 level 11.15 g/dL (IQR 10.23, 11.90) vs 12.00 g/dL (IQR 10.50, 13.85),  $p=0.01$ ]. Common  
12 clinical presentations of both PTB and EPTB were significant fever (27%), cough (33%) and  
13 weight loss (32%). However, only 20 (27%) of our patients presented with  $\geq 2$  significant  
14 symptoms. Patients with PTB were more likely to have significant cough whereas those with  
15 EPTB were more likely to present with significant fever and/or lymphadenopathy (Table 1).  
16 Twenty-eight patients (37%) had positive TB contact; 26 household contacts and 2 school  
17 contacts. Only 4 (5%) patients had  $\geq 2$  significant symptoms and positive contact history.

18 Abnormal CXR was found in 51 patients (68%) with the following changes: pulmonary  
19 infiltrates (n=24, 32%), hilar adenopathy (n=7, 9%), miliary (n=4, 5%), lobar collapse (n=3, 4%),  
20 pleural changes (n=2, 3%), cavitation (n=2, 3%), widened mediastinum (n=1, 1%) and  
21 combination of findings (n=8, 11%). Patients with PTB were more likely to have abnormal CXR  
22 compared to those with EPTB (84% vs 39%,  $p<0.01$ ).

1 More than half of PTB and EPTB had microbiologically proven disease (53% and 73%  
2 respectively). T-Spot was performed in 41 (55%) patients: 32 (78%) positive, 6 (15%) negative  
3 and 3 (7%) indeterminate. TST was performed in 31 patients (41%): 26 (84%) positive with  
4 median reading was 14.5 mm (IQR 11.0, 20.0). However, there were no significant differences in  
5 the percentage of positive smear, culture, PCR, TST or T-Spot disease between PTB and EPTB.  
6 There were no cases of MDR-TB in our cohort.

7 All patients received isoniazid and rifampicin with pyrazinamide and/or ethambutol. Patients  
8 with EPTB needed longer duration of treatment compared to those with PTB [Median 12 (IQR 9,  
9 12) vs 6 (IQR 6, 9) months,  $p < 0.01$ ]. Twelve (16.0%) patients were immunodeficient; Table 2  
10 describes the types of immunodeficiencies in both PTB and EPTB patients Patients who were  
11 immunodeficient were also treated for a longer period compared to immunocompetent patients  
12 [Median 12 (IQR 10, 12) vs 6 (IQR 6, 9) months,  $p < 0.01$ ].

13 Overall mortality rate was 8.0%. Mortality rate of PTB and EPTB was 4% and 15% respectively.  
14 Event-free survival in PTB patients compared to EPTB was 57% vs 27% ( $p = 0.01$ ). Of the 4  
15 deaths in EPTB, 2 patients (50%) had TB meningitis. Mortality rate of TB meningitis was 29%.  
16 Septic shock accounted for 3 out of 6 deaths in both PTB and EPTB. Table 3 describes the  
17 details of sequelae, mortality and relapse cases of PTB and EPTB.

## 1 DISCUSSION

2 Our study compares the demographics, clinical spectrum, investigation results and outcomes of  
3 PTB and EPTB.

4 The median age of patients with EPTB was significantly younger than PTB [Median age 5.05 vs  
5 10.10 years,  $p=0.03$ ], similar to another paediatric TB study (12). EPTB had lower recovery rate,  
6 high mortality, relapse and sequelae rates compared to PTB. Similar to other studies, this implied  
7 that younger children had higher risk of serious TB (13, 14). The mortality of TB meningitis  
8 from our review had decreased drastically from a peak of 60% in 1955 (7, 8). Mass BCG  
9 vaccination campaign, implemented in 1957, was one of the key interventions that led to a  
10 marked decrease in TB mortality rates, especially EPTB and for children < 5 years old (15, 16).  
11 A retrospective pediatric study in China showed that EPTB was more prevalent in the BCG  
12 unvaccinated group (59% vs 41%,  $p=0.05$ ); our small study failed to show any significant  
13 difference (12). This finding suggests that children who received BCG vaccination have less  
14 chance of contracting EPTB.

15 Children with TB rarely present with classical symptoms as seen in a survey from a high burden  
16 community (17). This is similar to our study in which only 27% of patients presented with  $\geq 2$   
17 out of 5 significant symptoms stated by South African Society for Pediatric Infectious Diseases  
18 (9). Marais et al stated that the index of suspicion should be increased when symptoms such as  
19 prolonged cough of more than 2 weeks, significant weight loss and fatigue exist together with  
20 positive TB contact (18). Four (5%) of our patients with TB had  $\geq 2$  significant symptoms and  
21 positive contact history. Nevertheless, available scoring systems should not be used for  
22 predicting pediatric TB infection as they lack sensitivity and specificity (19).

1  
2  
3 1 Sixty-eight percent of patients had abnormal CXR, which was higher than a large-scale  
4  
5 2 multicenter center study conducted in India (20). This can be explained by significant variation  
6  
7 3 between radiologists when interpreting pediatric CXR (21). Moreover, CXR had a high  
8  
9 4 sensitivity but low specificity for detecting active TB as many radiological changes seen in TB  
10  
11 5 could be present in other infections (22).

12  
13  
14  
15 6 A positive microbiological culture remains the gold standard for diagnosis of active TB but is  
16  
17 7 often limited by the prolonged turnover time. In this study, the percentage of patients with  
18  
19 8 eventual positive TB culture (49.0% and 57.5%) was more than those with  $\geq 1$  positive AFB  
20  
21 9 smear (26.5% and 28.0%) in both the PTB and EPTB group, which could lead to a delay in  
22  
23 10 identification and treatment of active TB disease. Our higher TB culture rates compared to  
24  
25 11 15.7% in China and 34% in USA could be due to more aggressive sampling methods or different  
26  
27 12 culture methods (12, 23).

28  
29  
30  
31  
32 13 Immunological investigations such as TST and IGRA can aid in the diagnosis of TB but each has  
33  
34 14 its own limitations. In children  $< 4$  years old, T-Spot is preferred as it has lower rate of  
35  
36 15 indeterminate results compared to QuantiFERON-TB test (24). While IGRA and TST are good  
37  
38 16 predictors of latent TB infection, their sensitivity for active TB infection are much more limited  
39  
40 17 (25, 26). Regardless of TST or IGRA results, treatment for TB should not be delayed if factors  
41  
42 18 are strongly suggestive of TB (contact history, radiologic and microbiologic) (27).

43  
44  
45  
46  
47 19 The limitations of this study were the small sample size and its retrospective nature. It was not  
48  
49 20 powered to correlate the effect of age, gender, and symptoms to laboratory results. This study  
50  
51 21 only included patients who received inpatient treatment for TB in KKH, potentially missing the  
52  
53 22 less severe group who received outpatient therapy.

54  
55  
56  
57 23

1  
2  
3 **1 CONCLUSION**  
4

5  
6 2 Extra-pulmonary TB is more common in the younger age group and is associated with lower  
7  
8 3 recovery rate. As TB culture has a long turnover time, treatment for TB should not be delayed if  
9  
10 4 other factors are strongly suggestive of TB. Clinicians should have a high index of suspicion for  
11  
12  
13 5 EPTB and should pay special attention to the younger age group.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 **1 What is already known on this topic**  
4  
5

6 2 Diagnosis of pediatric TB can be challenging as presentation ranges from non-specific symptoms  
7  
8 3 to severe clinical presentation. The proportion of EPTB has increased in the adult population.  
9  
10 4 However, little is known about the global impact of pediatric EPTB.  
11  
12  
13  
14  
15  
16

17 **6 What this study adds**  
18  
19

20 7 Common clinical presentations involving a third of patients with both PTB and EPTB were  
21  
22 8 significant fever, cough and weight loss. Patients with EPTB were more likely to be  
23  
24 9 immunodeficient. Extra-pulmonary TB is more common in the younger age group and is  
25  
26 10 associated with lower recovery rate.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 REFERENCES

1. Ministry of Health, Singapore. Communicable Diseases Surveillance in Singapore 2016, Singapore. p. 103 - 15.
2. Yang Z, Kong Y, Wilson F, Foxman B, Fowler AH, Marrs CF, et al. Identification of risk factors for extrapulmonary tuberculosis. *Clin Infect Dis*. 2004;38(2):199-205.
3. Gonzalez OY, Adams G, Teeter LD, Bui TT, Musser JM, Graviss EA. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. *Int J Tuberc Lung Dis*. 2003;7(12):1178-85.
4. World Health Organization. Global Tuberculosis Report 2015. Geneva; 2015. .
5. Sandgren A, Hollo V, van der Werf MJ. Extrapulmonary tuberculosis in the European Union and European Economic Area, 2002 to 2011. *Euro Surveill*. 2013;18(12).
6. Santiago-García B, Blázquez-Gamero D, Baquero-Artigao F, Ruíz-Contreras J, Bellón JM, Muñoz-Fernández MA, et al. Pediatric Extrapulmonary Tuberculosis: Clinical Spectrum, Risk Factors and Diagnostic Challenges in a Low Prevalence Region. *Pediatr Infect Dis J*. 2016;35(11):1175-81.
7. PAUL FM. Tuberculosis in B.C.G. vaccinated children in Singapore. *Arch Dis Child*. 1961;36:530-6.
8. Paul F. Tuberculosis meningitis in children in the Department of Paediatrics over a ten-year period. *Singapore Med J*. 1967;8(2):102-10.
9. Moore D, Hani C, H Hospital B, Schaaf S, Marais B, Moore D, et al. Childhood tuberculosis guidelines of the Southern African Society for Paediatric Infectious Diseases (SASPID)2009.
10. Chee CB, Gan SH, Khinmar KW, Barkham TM, Koh CK, Liang S, et al. Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. *J Clin Microbiol*. 2008;46(6):1935-40.
11. Chan DS, Choy MY, Wang S, Sng LH. An evaluation of the recovery of mycobacteria from urine specimens using the automated Mycobacteria Growth Indicator Tube system (BACTEC MGIT 960). *J Med Microbiol*. 2008;57(Pt 10):1220-2.
12. Wu X-R, Yin Q-Q, Jiao A-X, Xu B-P, Sun L, Jiao W-W, et al. Pediatric Tuberculosis at Beijing Children's Hospital: 2002–2010. *Pediatrics*. 2012;130(6):e1433.
13. Moyo S, Verver S, Mahomed H, Hawkridge A, Kibel M, Hatherill M, et al. Age-related tuberculosis incidence and severity in children under 5 years of age in Cape Town, South Africa. *Int J Tuberc Lung Dis*. 2010;14(2):149-54.
14. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric tuberculosis. *Lancet Infect Dis*. 2008;8(8):498-510.
15. Chew CH, Hu PY. BCG programme in the Republic of Singapore. *Singapore Med J*. 1974;15(4):241-5.
16. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. *JAMA*. 1994;271(9):698-702.
17. Marais BJ, Obihara CC, Gie RP, Schaaf HS, Hesselning AC, Lombard C, et al. The prevalence of symptoms associated with pulmonary tuberculosis in randomly selected children from a high burden community. *Arch Dis Child*. 2005;90(11):1166-70.
18. Marais BJ, Gie RP, Hesselning AC, Schaaf HS, Lombard C, Enarson DA, et al. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. *Pediatrics*. 2006;118(5):e1350-9.
19. Hesselning AC, Schaaf HS, Gie RP, Starke JR, Beyers N. A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. *Int J Tuberc Lung Dis*. 2002;6(12):1038-45.

- 1  
2  
3 1 20. Swaminathan S, Datta M, Radhamani MP, Mathew S, Reetha AM, Rajajee S, et al. A profile of  
4 2 bacteriologically confirmed pulmonary tuberculosis in children. *Indian Pediatr.* 2008;45(9):743-7.  
5 3 21. Hoog AH, Meme HK, van Deutekom H, Mithika AM, Olunga C, Onyino F, et al. High sensitivity of  
6 4 chest radiograph reading by clinical officers in a tuberculosis prevalence survey. *Int J Tuberc Lung Dis.*  
7 5 2011;15(10):1308-14.  
8 6 22. Piccasso R, Paparo F, Garlaschi G. Diagnostic accuracy of chest radiography for the diagnosis of  
9 7 tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review. *J Rheumatol*  
10 8 *Suppl.* 2014;91:32-40.  
11 9 23. Winston CA, Menzies HJ. Pediatric and Adolescent Tuberculosis in the United States, 2008–2010.  
12 10 *Pediatrics.* 2012;130(6):e1425.  
13 11 24. Bergamini BM, Losi M, Vaienti F, D'Amico R, Meccugni B, Meacci M, et al. Performance of  
14 12 commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents.  
15 13 *Pediatrics.* 2009;123(3):e419-24.  
16 14 25. Connell T, Tebruegge M, Ritz N, Curtis N. Interferon-gamma release assays for the diagnosis of  
17 15 tuberculosis. *Pediatr Infect Dis J.* 2009;28(8):758-9.  
18 16 26. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis  
19 17 infection: areas of uncertainty and recommendations for research. *Ann Intern Med.* 2007;146(5):340-54.  
20 18 27. Perez-Velez CM, Marais BJ. Tuberculosis in Children. *New England Journal of Medicine.*  
21 19 2012;367(4):348-61.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 **Table 1. Comparison of Pulmonary and Extra-pulmonary TB**

	Pulmonary N= 49 (%)	Extra-pulmonary N= 26 (%)	P value
Median age (years)	10.1 (IQR 3.5, 13.5)	5.1 (IQR 1.2, 10.2)	0.03
Gender			0.82
Males	25 (51)	14 (54)	
Females	24 (49)	12 (46)	
Nationality			0.21
Singapore residents	37 (76)	16 (62)	
Non-Singapore residents	12 (24)	10 (38)	
Received BCG vaccine	41 (89)	19 (76)	0.14
Comorbidities			<0.01
Immunodeficient	3 (6)	9 (35)	
Not immunodeficient	46 (94)	17 (65)	
Contact history			0.06
Positive contact	22 (45)	6 (23)	
No contact history	27 (55)	20 (77)	
Symptoms			
Significant fever	9 (19)	11 (48)	0.01
Significant cough	22 (51)	3 (14)	<0.01
Significant weight loss	18 (39)	6 (27)	0.34
Median weight loss (%body weight)	10.6 (IQR 5.8, 20.0)	16.3 (IQR 13.6, 40.6)	0.29
Fatigue	2 (4)	2 (8)	0.60
Lymphadenopathy	2 (4)	8 (31)	<0.01
≥ 2 symptoms stated above	14 (29)	5 (23)	0.61
No symptom stated above	22 (45)	11 (42)	0.83
Hematological results			
Median hemoglobin (g/dL)	12.0 (IQR 10.5, 13.9)	11.2 (IQR 10.2, 11.9)	0.03
Median white blood cells (x10 <sup>9</sup> /L)	11.2 (IQR 7.5, 15.6)	10.2 (IQR 7.6, 12.0)	0.15
Median Platelet (x10 <sup>9</sup> /L)	376.5 (IQR 281.5, 451.0)	377.0 (IQR 339.5, 507.0)	0.38
Median ESR (mm/hr)	40.0 (IQR 15.0, 85.0)	34.0 (IQR 19.0, 54.5)	0.61
Median CRP (mg/L)	36.0 (IQR 16.5, 84.4)	32.4 (IQR 8.6, 69.3)	0.43
Immunological results			
Positive TST	20 (41)	6 (23)	0.10
Positive IGRA	20 (41)	12 (46)	0.80
Microbiological			0.10
Microbiologically proven	26 (53)	19 (73)	
Not microbiologically proven	23 (47)	7 (27)	
Microbiological results			
≥ 1 site/sample positive AFB smear	13 (27)	7 (28)	0.89
≥ 1 site/sample positive AFB culture	24 (49)	15 (58)	0.47
≥ 1 site/sample positive TB PCR	14 (40)	12 (60)	0.15
Abnormal CXR	41 (84)	10 (39)	<0.01
Treatment outcome			
Recovered	28 (57)	7 (27)	0.01
Death	2 (4)	4 (15)	0.17
Relapsed	1 (2)	1 (4)	-
Sequelae	10 (20)	9 (35)	0.18
Lost to follow up	8 (16)	3 (12)	0.73
Still completing treatment	0 (0)	2 (8)	-
Median duration of treatment (months)	6.0 (IQR 6.0, 9.0)	12.0 (IQR 9.0, 12.0)	<0.01

2

1 **Table 2. Types of immunodeficiencies in Pulmonary and Extra-pulmonary TB**

Types of immunodeficiencies	Pulmonary N= 49 (%)	Extra-pulmonary N= 26 (%)
HIV	2 (4)	2 (8)
Malignancy	0 (0)	2 <sup>b</sup> (8)
Primary immune deficiency	0 (0)	2 <sup>c</sup> (8)
Others	1 <sup>a</sup> (2)	3 <sup>d</sup> (12)

2 <sup>a</sup> Ebstein Barr Virus-related haemophagocytic lymphohistiocytosis

3 <sup>b</sup> 1 Medulloblastoma on chemotherapy, 1 Neuroblastoma on chemotherapy

4 <sup>c</sup> Severe combined immunodeficiency

5 <sup>d</sup> 1 Crohn's disease on immunosuppressant, 1 Juvenile idiopathic arthritis on biologics, 1 Mendelian susceptibility to  
6 mycobacterial disease

8 **Table 3. Outcomes of Pulmonary and Extra-pulmonary TB**

	Pulmonary N = 49		Extrapulmonary N = 26			
		n	%	n	%	
Types of sequelae	Bronchus compression	3	6	Intestinal perforation	1	4
	Bronchiectasis	3	6	Kyphosis	1	4
	Restrictive lung disease	2	4	CNS infarct	1	4
	Complications from underlying condition	2	4	Complications from underlying condition	2	8
Reasons for mortality <sup>a</sup>	Septic shock	1	2	Septic Shock	2	8
	Pulmonary haemorrhage	1	2	Severe Cerebral edema	1	4
				Underlying malignancy	1	4
Reasons for relapse	Reactivation of pulmonary TB with pericarditis (cause unknown)	1	2	Recurrent TB lymphadenitis (cause unknown)	1	4

9 <sup>a</sup> Of 4 EPTB: 2 TB meningitis, 1 pericardial TB, 1 multiorgan TB